

1 **Evolution of long-term vaccine induced and hybrid immunity in healthcare**  
2 **workers after different COVID-19 vaccination regimens: a longitudinal**  
3 **observational cohort study**

4  
5 Shona C. Moore<sup>1\*</sup>, Barbara Kronsteiner<sup>2,3\*</sup>, Stephanie Longet<sup>4,5\*</sup>, Sandra Adele<sup>\*2,3</sup>,  
6 Alexandra S. Deeks<sup>2,6</sup>, Chang Liu<sup>5,24</sup>, Wanwisa Dejnirattisai<sup>5,7</sup>, Laura Silva Reyes<sup>8</sup>, Naomi  
7 Meardon<sup>9</sup>, Sian Faustini<sup>10</sup>, Saly Al-Taei<sup>10</sup>, Tom Tipton<sup>4,5</sup>, Luisa M Hering<sup>1</sup>, Adrienn Angyal<sup>11</sup>,  
8 Rebecca Brown<sup>11</sup>, Alexander R Nicols<sup>12</sup>, Susan L Dobson<sup>1</sup>, Piyada Supasa<sup>5</sup>, Aekkachai  
9 Tuekprakhon<sup>5</sup>, Andrew Cross<sup>13</sup>, Jessica K Tyerman<sup>12</sup>, Hailey Hornsby<sup>11</sup>, Irina Grouneva<sup>11</sup>,  
10 Megan Plowright<sup>9,11</sup>, Peijun Zhang<sup>11</sup>, Thomas A.H. Newman<sup>9,11</sup>, Jeremy M. Nell<sup>14</sup>, Priyanka  
11 Abraham<sup>2,3</sup>, Mohammad Ali<sup>2,3</sup>, Tom Malone<sup>2</sup>, Isabel Neale<sup>2,3</sup>, Eloise Phillips<sup>2</sup>, Joseph D.  
12 Wilson<sup>2,6,15</sup>, Sam M. Murray<sup>2</sup>, Martha Zewdie<sup>2</sup>, Adrian Shields<sup>10,16</sup>, Emily C. Horner<sup>17</sup>, Lucy  
13 H. Booth<sup>17</sup>, Lizzie Stafford<sup>5</sup>, Sagida Bibi<sup>8</sup>, Daniel G. Wootton<sup>1,13,18</sup>, Alexander J. Mentzer<sup>5,6</sup>,  
14 Christopher P. Conlon<sup>3,5</sup>, Katie Jeffery<sup>6,19</sup>, Philippa C. Matthews<sup>2,20,21,22</sup>, Andrew J.  
15 Pollard<sup>5,8,23</sup>, Anthony Brown<sup>2</sup>, Sarah L. Rowland-Jones<sup>9,11</sup>, Juthathip Mongkolsapaya<sup>5,24</sup>,  
16 Rebecca P. Payne<sup>12</sup>, Christina Dold<sup>8,23</sup>, Teresa Lambe<sup>8,24</sup>, James E.D. Thaventhiran<sup>17</sup>, Gavin  
17 Sreaton<sup>5,24</sup>, Eleanor Barnes<sup>2,6,23,25</sup>, Susan Hopkins<sup>26,27,28</sup>, Victoria Hall<sup>26,28</sup>, Christopher JA  
18 Duncan<sup>12,14</sup>†, Alex Richter<sup>10,16</sup>†, Miles Carroll<sup>4,5</sup>†, , Thushan I. de Silva<sup>9,11</sup>†, Paul  
19 Klenerman<sup>2,6,23,25</sup>†^, Susanna Dunachie<sup>2,3,6,29</sup>†, Lance Turtle<sup>1,13</sup>†^ on behalf of the PITCH  
20 Consortium+

21

- 22 1. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute  
23 of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
- 24 2. Peter Medawar Building for Pathogen Research, Nuffield Dept. of Clinical Medicine,  
25 University of Oxford, UK
- 26 3. Oxford Centre For Global Health Research, Nuffield Dept. of Clinical Medicine,  
27 University of Oxford, UK
- 28 4. Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford,  
29 UK
- 30 5. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of  
31 Oxford, UK
- 32 6. Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 33 7. Division of Emerging Infectious Disease, Faculty of Medicine Siriraj Hospital, Mahidol  
34 University, Bangkok, Thailand
- 35 8. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
- 36 9. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- 37 10. Institute for Immunology and Immunotherapy, College of Medical and Dental  
38 Science, University of Birmingham, UK
- 39 11. Department of Infection, Immunity and Cardiovascular Disease, University of  
40 Sheffield, UK
- 41 12. Translational and Clinical Research Institute, Immunity and Inflammation Theme,  
42 Newcastle University, UK
- 43 13. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 44 14. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS  
45 Foundation Trust, UK
- 46 15. Oxford University Medical School, Medical Sciences Division, University of Oxford,  
47 Oxford, UK

- 48 16. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK  
49 17. MRC Toxicology Unit, University of Cambridge, Cambridge, UK  
50 18. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK  
51 19. Radcliffe Department of Medicine, University of Oxford, UK  
52 20. The Francis Crick Institute, London, UK  
53 21. Division of Infection and Immunity, University College London, London, UK  
54 22. Department of Infectious Diseases, University College London Hospital NHS  
55 Foundation Trust, London, UK  
56 23. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK  
57 24. Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of  
58 Oxford, Oxford, UK  
59 25. Translational Gastroenterology Unit, University of Oxford, UK  
60 26. UK Health Security Agency, London, UK  
61 27. Faculty of Medicine, Department of Infectious Disease, Imperial College London, UK  
62 28. NIHR Health Protection Research Unit in Healthcare Associated Infection and  
63 Antimicrobial Resistance, University of Oxford, UK  
64 29. Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand

65

66 \*These authors contributed equally

67 †Senior Author

68 ^Corresponding authors:

69 Lance Turtle, Ronald Ross Building, Department of Clinical Infection, Microbiology and  
70 Immunology, University of Liverpool, 8 West Derby Street, L69 7BE.

71 [lance.turtle@liverpool.ac.uk](mailto:lance.turtle@liverpool.ac.uk)

72 Paul Klenerman, Peter Medawar Building for Pathogen Research, University of Oxford,  
73 Oxford OX1 3SY, UK. [paul.klenerman@ndm.ox.ac.uk](mailto:paul.klenerman@ndm.ox.ac.uk)

74

#### 75 **Secondary Author List**

76 Hibatullah Abuelgasim, Emily Adland, Zahra Ahmed, Hossain Delowar Akther, Ahmed  
77 Alhussni, Ali Amini, M. Azim Ansari, Rachel Anslow, Carolina V. Arancibia-Cárcamo, Ana  
78 Atti, James Austin, Angela Bailey, Martin Bayley, Alice Bridges-Webb, Helen Brown, Holly  
79 Caborn, Jeremy Chalk, Meera Chand, Anu Chawla, Senthil Chinnakannan, Elizabeth  
80 Clutterbuck, Debbie Cross, Joseph Cutteridge, Sophie Davies, Catherine de Lara, Lucy  
81 Denly, Ben Diffey, Stavros Dimitriadis, Timothy Donnison, Thomas M Drake, Maeva Dupont,  
82 Elena Efstathiou, David Eyre, Alex Fairman, Sarah Foulkes, John Frater, Siobhan Gardiner,  
83 Javier Gilbert-Jarmillo, Philip Goulder, Jessica Gregory, Carl-Philipp Hackstein, Sophie  
84 Hambleton, Muzlifah Haniffa, Helen Hanson, Kate Harrington, Jenny Haworth, Carole Hays,  
85 Jennifer Holmes, Fatima Mariam Ilyas, Jasmin Islam, Anni Jämsén, Chris Jones, Geraldine  
86 Jones, Mwila Kasanyinga, Sinead Kelly, Maqsood Khan, Jon Kilby, Rosemary Kirk, Michael  
87 L. Knight, Allan Lawrie, Lian Lee, Lauren Lett, Katy Lillie, Nicholas Lim, Alison Lye,  
88 Spyridoula Marinou, Chloe Matthewman, Jessica McNeill, Gracie Mead, Hema Mehta,  
89 Haniffa Muzlifah, Christopher Norman, Denise O'Donnell, Ane Ogbe, Juyeon Park, Brendan  
90 A. I. Payne, Gareth Platt, Sonia Poolan, Nicholas Provine, Narayan Ramamurthy, Nichola  
91 Robinson, Leigh Romaniuk, Patpong Rongkard, Ayoub Saei, Oliver L. Sampson, Donal  
92 Skelly, Jarmila S. Spegarova, Gareth Stephens, Emily Stephenson, Rachel Stimpson,  
93 Krishanthi Subramaniam, Chloe Tanner, Lydia J. Taylor, Chitra Tejpal, Sarah Thomas, Neal  
94 Townsend, Simon Travis, Nicola Trewick, Stephanie Tucker, Helena Turton, Zara Valiji,

95 Adam Watson, Lisa Watson, Esme Weeks, Rachel Whitham, Jayne Willson, Barbara  
96 Wilson, Robert Wilson, Steven Wood, Huiyuan Xiao, Amira A. T. Zawia  
97

98 **Abstract**

99

100 Both infection and vaccination, alone or in combination, generate antibody and T cell  
101 responses against SARS-CoV-2. However, the maintenance of such responses –  
102 and hence protection from disease – requires careful characterisation. In a large  
103 prospective study of UK healthcare workers (Protective immunity from T cells in  
104 Healthcare workers (PITCH), within the larger SARS-CoV-2 immunity & reinfection  
105 evaluation (SIREN) study) we previously observed that prior infection impacted  
106 strongly on subsequent cellular and humoral immunity induced after long and short  
107 dosing intervals of BNT162b2 (Pfizer/BioNTech) vaccination. Here, we report longer  
108 follow up of 684 HCWs in this cohort over 6-9 months following two doses of  
109 BNT162b2 or AZD1222 (Oxford/AstraZeneca) vaccination and up to 6 months  
110 following a subsequent mRNA booster vaccination. We make three observations:  
111 Firstly, the dynamics of humoral and cellular responses differ; binding and  
112 neutralising antibodies declined whereas T and memory B cell responses were  
113 maintained after the second vaccine dose. Secondly, vaccine boosting restored IgG  
114 levels, broadened neutralising activity against variants of concern including omicron  
115 BA.1, BA.2 and BA.5, and boosted T cell responses above the 6 month level post  
116 dose 2. Thirdly, prior infection maintained its impact driving larger as well as broader  
117 T cell responses compared with never-infected people – a feature maintained until 6  
118 months after the third dose. In conclusion, broadly cross-reactive T cell responses  
119 are well maintained over time – especially in those with combined vaccine and  
120 infection-induced immunity (“hybrid” immunity) – and may contribute to continued  
121 protection against severe disease.

122

123

124

## 125 INTRODUCTION

126 As vaccines have been deployed to tackle the SARS-CoV-2 pandemic, crucial  
127 questions have emerged regarding long-term maintenance of protective immunity  
128 against disease. The appearance of viral variants leading to successive waves of  
129 infection has clearly shown the limits of vaccine protection against infection (UK  
130 Health Security Agency, 2022). Despite this, vaccine protection against severe  
131 disease has been well maintained across the recent delta (Tartof et al., 2021) and  
132 omicron BA.1 (Andrews et al., 2022) waves. To understand the underlying immune  
133 responses that determine these population-level observations, large-scale studies of  
134 individuals with high exposure to SARS-CoV-2, such as health care workers  
135 (HCWs), can provide valuable insights as has been demonstrated by the SARS-  
136 CoV-2 immunity & reinfection evaluation (SIREN) study in the UK (Hall et al., 2022;  
137 Hall et al., 2021a; Hall et al., 2021b). Protective Immunity from T Cells in Healthcare  
138 workers (PITCH), a study aligned closely with SIREN, is focused on the longitudinal  
139 analysis of antiviral T and B cell responses after infection and/or vaccination with  
140 BNT162b2 (Pfizer/BioNTech) or AZD1222 (Oxford/AstraZeneca). PITCH has already  
141 provided data indicating that the extended interval vaccine regimen for BNT162b2  
142 mRNA vaccine deployed in the UK was associated with enhanced antibody and  
143 CD4<sup>+</sup> T cell helper responses (Payne et al., 2021a). All immune responses were  
144 strongly enhanced by prior SARS-CoV-2 infection.

145  
146 The long-term impacts of prior exposure, vaccine regimen and vaccine type have not  
147 been fully defined, especially at the level of T cell responses. Characterising the  
148 response to vaccines and infections in healthy people is essential to determine future  
149 vaccination policies, while identification of vulnerable non-responders can inform  
150 additional interventions such as extra booster doses of vaccine and/or monoclonal  
151 antibody therapies. Correlations with protection from infection at a population level  
152 have been observed for binding (Earle et al., 2021; Gilbert et al., 2022) and  
153 neutralising antibodies (Addetia et al.; Feng et al., 2021; Gilbert et al., 2022; Khoury  
154 et al., 2021; Moore et al., 2021). The role of other, non-neutralising antibody  
155 functions, such as antibody-dependent NK cell activity, antibody-dependent  
156 phagocytosis or complement deposition, requires further investigation (Ewer et al.,  
157 2021; Kaplonek et al., 2022a; Tomic et al., 2022). However, monitoring of SARS-  
158 CoV-2 specific T cell immunity is also essential, as T cell defence is potentially a key  
159 explanation for lower case hospitalisation and mortality for the omicron variant  
160 compared with earlier variants (Nyberg et al., 2022), despite omicron's high mortality  
161 in unvaccinated populations (Mefsin et al., 2022). T cells are a cornerstone of  
162 antiviral defence, orchestrating the immune response including cytotoxic activity  
163 against virally infected cells and optimising production of antibodies from B cells  
164 (Sette and Crotty, 2021). Macaque (McMahan et al., 2021) and human (Kedzierska  
165 and Thomas, 2022; Molodtsov et al., 2022; Rydyznski Moderbacher et al., 2020)  
166 studies support this key role for T cells in protection against the severe effects of  
167 SARS-CoV-2 infection, potentially alongside functional antibody properties beyond  
168 neutralisation (Bartsch Yannic et al.; Kaplonek et al., 2022b). In some cases, cross-

169 reactive T cells are associated with protection against infection in exposed  
170 seronegative groups (Kundu et al., 2022). There is also evidence of SARS-CoV-2  
171 specific cell responses in highly exposed HCW without seroconversion (Ogbe et al.,  
172 2021), and expansion of pre-existing RNA-polymerase-specific T cells in  
173 seronegative SARS-CoV-2 infection (Swadling et al., 2022).

174

175 There is a body of emerging data on the waning of antibody responses, especially  
176 after the shorter dose interval regimen for BNT162b2 (Goldberg et al., 2021; Naaber  
177 et al., 2021). Waning of antibody is associated with loss of protection against  
178 infection (Hall et al., 2022; Wei et al., 2022b), whereas protection against severe  
179 disease is relatively well maintained (Andrews et al., 2022; Carazo et al., 2022; Lin et  
180 al., 2022; Rosenberg et al., 2021; Tartof et al., 2021; UK Health Security Agency,  
181 2022). T cell responses to spike protein post vaccination do not correlate strongly  
182 with binding or neutralising antibody responses (Payne et al., 2021a). Importantly,  
183 whilst antibodies generated in response to vaccination neutralise omicron much less  
184 well than the ancestral strain (Dejnirattisai et al., 2022; Schmidt et al., 2021), the T  
185 cell response to SARS-CoV-2 is minimally impacted by mutations in the alpha, beta,  
186 gamma and delta variants of concern (Payne et al., 2021a; Skelly et al., 2021), and  
187 75-85% preserved against the omicron BA.1 variant (De Marco et al., 2022; Gao et  
188 al., 2022; GeurtsvanKessel Corine et al., 2022; Keeton et al., 2022; Liu et al., 2022;  
189 Madelon et al., 2022; Tarke et al., 2022). Given that at this point in the pandemic,  
190 public health decisions are increasingly being made around limiting severe disease  
191 rather than preventing milder infections in the community, having robust data at  
192 scale that indicates the trajectory of the T cell responses after different vaccine  
193 regimens is of increasing value. The impact of subsequent vaccine dosing on T and  
194 B cell responses is additionally a key focus in such decision making.

195

196 We previously observed higher anti-spike binding, higher neutralising antibody  
197 responses and lower spike-specific T cell magnitude but increased IL2 production  
198 one month after second dose when BNT162b2 was delivered with a longer dosing  
199 interval (median 10 weeks) compared to the licensed shorter (3-4 weeks) interval  
200 (Payne et al., 2021a). This pattern was reproduced in an elderly population (Parry et  
201 al., 2022), and the antibody findings have been confirmed in the larger SIREN cohort  
202 (Otter et al., 2022). Evidence of improved vaccine effectiveness with a longer dose  
203 interval was reported in a study of two Canadian provinces (Skowronski et al., 2022).

204

205 In the study presented here, our objective was to explore the characteristics of  
206 adaptive and humoral immunity following two and three vaccine doses, to consider  
207 the longer-term impacts of regimen variation, vaccine type (including the Oxford-AZ  
208 ChadOx1-based vaccine) and infection over time. We observed the long-term impact  
209 of prior infection even after two doses of vaccine, which is consistent with protection  
210 documented in SIREN (Hall et al., 2022). We saw no decline in T cell responses over  
211 time regardless of vaccine regimen — this contrasts with waning of both binding and  
212 neutralising antibody (NAb) titres, which remained strongest and broadest in the long

213 interval BNT162b2 group. The third dose of vaccine boosted binding antibody  
214 responses such that differences seen between vaccine regimens after only two  
215 doses were reduced as were differences associated with prior infection. Overall, the  
216 data indicate a stable pool of T cell memory is induced and maintained across  
217 vaccine types/regimens, consistent with the sustained impact of vaccination with or  
218 without prior infection in protection against severe disease.

219

## 220 **RESULTS**

221

222 *Participants vaccinated with a primary course and a booster dose of COVID vaccine*

223 We studied 684 participants who had been vaccinated with a primary course of  
224 COVID-19 vaccine between 9th December 2020 and 23rd May 2021 (Table 1 and  
225 Figure 1). In total, 592 participants received a primary course of BNT162b2 vaccine  
226 (Pfizer), of whom 84 participants received the second dose of BNT162b2 vaccine  
227 after a short (3-5 week, median 24 days) interval, and 508 participants received the  
228 second dose of BNT162b2 vaccine after an extended (6-17 week, median 71 days)  
229 interval (Payne et al., 2021a). 92 participants received a primary course of AZD1222  
230 vaccine administered with an interval of 7-23 weeks (median 74 days). The median  
231 age of all participants was 43 (range 22-77), and 73.8% of participants were female,  
232 reflecting the demographic of healthcare workers in the UK and consistent with our  
233 previous reports, and the wider SIREN cohort.

234

235 *Symptomatic infection and asymptomatic anti-nucleocapsid (N) seroconversion were*  
236 *common during the study period*

237 During follow up of this cohort (May 2021 to March 2022), some participants became  
238 infected during the SARS-CoV-2 waves of delta and omicron BA.1 or BA.2 (Table 1).  
239 33 participants developed symptomatic COVID-19 confirmed by positive SARS-CoV-  
240 2 PCR assay. A further 49 participants had evidence of asymptomatic infection  
241 between one and 6 months after the second vaccine, reflected by SARS-CoV-2 N  
242 antibody seroconversion detected in the 6 month samples. After accounting for those  
243 infections, half the cohort (342 participants) met the definition of infection-naïve at  
244 the time of the third vaccination. In addition, 11 participants of 21 followed up to 6  
245 months post third dose became infected with omicron variants.

246

247 We measured T cell responses 6 months after the second vaccine dose and found  
248 that participants infected between one and 6-months after the second dose had  
249 similar T cell responses to those infected prior to their first vaccine dose (Figure S2).  
250 Spike IgG, measured by MesoScale Discovery (MSD), was lower in those infected  
251 during the study compared with those infected before vaccination, but was higher  
252 than infection naïve participants. Therefore, in this report, participants with natural  
253 infection at any point were analysed together as a “hybrid immunity” group,  
254 regardless of when the infection occurred in relation to vaccine doses.

255

256 *Six months post second vaccination, T cell IFN $\gamma$  ELISpot responses are greatest*  
257 *following BNT162b2 short dose interval at six months and are augmented in*  
258 *participants with hybrid immunity*

259 In infection-naïve participants, at 6 months post vaccine dose 2, there was no  
260 significant difference in the T cell response by IFN $\gamma$  ELISpot assay between the  
261 three primary vaccine groups, although there was a trend towards higher T cell  
262 responses in those who received BNT162b2 vaccine with a short interval (median 3  
263 weeks) than those groups who were vaccinated with a BNT162b2 long interval  
264 (median 10 weeks), or the group vaccinated with AZD1222 (Figure 2A). This  
265 difference was significant for the BNT162b2 short and long interval groups one  
266 month after the second dose (Payne et al., 2021a). Spike-specific T cell responses 6  
267 months after the second vaccination were considerably greater in all groups (105  
268 SFU/10<sup>6</sup> PBMC, IQR 48 – 240) than the historical median responses we observed  
269 using the same assay in this cohort pre-vaccination in 2020 (Tomic et al., 2022) 6  
270 months after wave 1 infection (44 SFU/10<sup>6</sup> PBMC, IQR 1-107).

271  
272 For anti-spike binding antibody responses, levels were higher for BNT162b2  
273 recipients than AZD1222 recipients irrespective of the dosing interval (Figure 2B). A  
274 similar pattern was apparent for RBD antibody (Figure 2C). As was observed at one  
275 month post second dose, T cell and antibody responses were greater in magnitude  
276 in those who were previously infected at any point before the 6-month post second  
277 dose sample was collected (Figure 2A-C). T cell responses against M and N were,  
278 as expected, higher in those with hybrid immunity, and correlated with N antibody  
279 levels (Figure 2D).

280  
281 *After a booster (third) vaccine, IFN $\gamma$  ELISpot T cell responses are equivalent in all*  
282 *groups irrespective of primary vaccine regimen*

283 Over the 6-month period following the second vaccine dose, T cell IFN $\gamma$  responses  
284 were well maintained, with a modest fall which did not reach statistical significance,  
285 and, overall, were boosted significantly after the third dose in both naïve and hybrid  
286 immune participants (Figure 3A). This apparent boost was accounted for by the  
287 largest group, the BNT162b2 long interval group (Supplementary Figure S3A, D and  
288 G), whilst the other, smaller, groups did not achieve statistical significance. These  
289 responses were well maintained for 6 months following the third dose, with no  
290 significant change in T cell response between 1 and 6 months post third dose,  
291 although fewer hybrid immune participants were tested at this timepoint (Figure 3A).  
292 One month after the third vaccine dose, participants receiving all three vaccine  
293 regimens had equivalent T cell IFN $\gamma$  responses (Figure 3D). The post dose 3  
294 boosting effect did not generate T cell responses any higher than those measured 28  
295 days post dose 2, but responses were higher than those measured 6 months post  
296 dose 2 value. Thus, all groups derived a detectable benefit on the T cell response  
297 from the third vaccine dose.

298



299 *Infection leads to boosting of IFN $\gamma$  ELISpot T cell responses following all vaccine*  
300 *regimens*

301 Spike-specific T cell responses were higher in those with hybrid immunity compared  
302 with infection naïve. This was the case for both BNT162b2 vaccinated groups  
303 (Supplementary Figure S3A and D) but was not the case in the AZD1222 group  
304 (Supplementary Figure S3G). T cell responses were still higher one month post dose  
305 3 in those who had been previously infected with SARS-CoV-2 (Figure 3A).  
306 However, by 6 months post dose 3 the spike-specific T cell response in naïve and  
307 hybrid immune participants was equivalent (Figure 3A). M and N responses were  
308 higher in BNT162b2 vaccinated participants with hybrid immunity, but this difference  
309 was not seen in the AZD1222 group. Between one month post dose 2 and one  
310 month post dose 3, even in the group who did not seroconvert to N, we detected a  
311 rise in the T cell response to M and N in the BNT162b2 long interval naïve group (the  
312 largest group), which became significant one month after the third dose  
313 (Supplementary Figure S4D), and appeared to increase still further at the 6 month  
314 time point (although this was not significant). Given that T cell responses are more  
315 sustained than antibody responses, this presumably reflects people who became  
316 asymptotically infected but whose subsequent samples were taken after waning  
317 of the N antibody response. We saw no such change in the AZD1222 group  
318 (Supplementary Figure S4G).

319

320 *Humoral responses wane quickly but are boosted by third dose vaccination*

321 After the second vaccine dose, binding antibody responses decreased sharply. The  
322 median SARS-CoV-2 spike IgG titre (MSD) decreased 5.6-fold in naïve vaccine  
323 recipients and 3.3-fold in the hybrid immunity group by 6 months (Figure 3B).  
324 Participants who received the different vaccine regimens followed similar patterns  
325 (Figure S3B, E and H). Naïve participants who received AZD1222 had lower spike  
326 antibody titres post second dose than those receiving BNT162b2 regimens, but  
327 these titres were then boosted 25-fold by the third (BNT162b2 mRNA) vaccine dose  
328 (Figure S3H). One month after the third dose, spike antibody IgG binding levels  
329 increased back to similar levels to those measured one month post dose 2 (Figure  
330 3B). By 6 months after the third dose, the rate of waning was less than after the  
331 second dose, and was less in the naïve group than in the hybrid immune group. The  
332 naïve group waned by 1.4-fold between one and 6 months after the third dose, which  
333 was not significant, compared with 5.8-fold after the second dose. The hybrid  
334 immune group waned 1.9-fold between one and 6 months post dose 3, compared  
335 with 3.2-fold in the equivalent period after the second dose. The reduction was  
336 significant for the hybrid group, and brought it down to a level equivalent to that of  
337 the naïve group by 6 months post dose 3.

338

339 After the third dose, there was no significant difference in the magnitude of the spike  
340 binding IgG response between vaccine regimens (Figure 3E). Overall, a subtle (1.4-  
341 fold) but significant increase in spike IgG remained between previously infected and  
342 naïve participants one month after the third dose (Figure 3B). The IgG levels

343 measured post dose 3 were significantly greater than those measured post dose 2 in  
344 naïve participants, but those with hybrid immunity did not derive additional benefit  
345 from the levels one month post dose 2, although there was a substantial boost over  
346 the 6 month post dose 2 level in this group. The RBD binding response followed the  
347 same pattern as the total spike response (Supplementary Figure S4B, E, H) and N  
348 antibody titres were unchanged by vaccination in the hybrid immune group  
349 (Supplementary Figure S4C, F, I). However, some of the naïve participants did show  
350 rises in N antibody between one and 6 months post third dose. This time period  
351 corresponded to the very large wave of omicron BA.1 in the UK, and likely  
352 represents subclinical infection in some of our participants.

353

354 Memory B cell responses were measured by IgG ELISpot in a subset of 106  
355 participants (Figure 3C, Supplementary Figure S3C, F and I). Six months after the  
356 second dose, memory B cell frequencies were similar between naïve and hybrid  
357 immunity group, and these responses were preserved, with no statistically significant  
358 difference from one month post second dose. In the whole dataset, memory B cell  
359 responses were not impacted by the third vaccine dose, though there was a  
360 significant increase in the BNT162b2 long interval and AZD1222 groups in both  
361 naïve participants, (Supplementary Figure S3F and I), and in the BNT162b2 long  
362 interval participants with hybrid immunity (Supplementary Figure S3F). Unlike the T  
363 cell IFN $\gamma$  response, where there was still an advantage in those previously infected,  
364 there was no increase in the memory B cell response in those previously infected in  
365 any group (Figure 3C and F).

366

367 These data indicate that although antibody levels decline between the second and  
368 third vaccine doses, T and B cell responses are well maintained across this period.  
369 Hybrid immunity conferred an advantage on the magnitude of the T cell and antibody  
370 response at all timepoints, including after the third vaccine dose, but did not for the B  
371 cell response. The third vaccine dose boosted immunity back to previous levels, or  
372 greater, with a tendency to even out any earlier differences between two-dose  
373 vaccine regimens.

374

375 Our cohort was mostly female, but the BNT162b2 short interval group contained  
376 significantly more male participants (30 of 84, 40.5%,  $p=0.006$ , Chi squared test,  
377 Table 1). We did not detect any significant differences in responses between the  
378 three vaccine regimens, but to ensure that there was no potential for the imbalance  
379 in male participants to influence this, we ran regression models to investigate the  
380 influence of age, sex, previous SARS-CoV-2 infection and vaccine regimen on  $\log_{10}$   
381 transformed spike-specific IgG and T cell responses (see Supplementary Table  
382 regression analysis). Multivariable models indicated that previous infection was  
383 independently associated with both IgG and T cell responses, but that male sex was  
384 inversely associated with T cell responses (Supplementary Tables 1A and E).  
385 Multivariable models were used to explore the effect of sex within each vaccine  
386 regimen group, for IgG and T cell responses. Sex had no effect on IgG responses in

387 all three vaccine groups (Supplementary Tables 1B, C and D). Responses were  
388 negatively associated with age and associated with previous infection in the  
389 BNT162b2 long interval group. For T cell responses, previous infection was  
390 associated with T cell responses in the BNT162b2 groups, and male sex was  
391 negatively associated with T cell responses only in the AZD1222 group (Table 2C).  
392 Therefore, the male imbalance did not affect the measurement of responses in the  
393 BNT162b2 short interval group. Although we found evidence that T cell responses to  
394 a booster mRNA vaccine are weaker in men who have received a primary course of  
395 AZD1222, this must be viewed with caution as it is based on only 24 participants.

396

397 *Polyfunctional T cell responses are detectable six months after vaccination, with*  
398 *enhancement in individuals with hybrid immunity*

399 T cell responses measured by intracellular cytokine staining (ICS) were lower at 6  
400 months post second dose in AZD1222 vaccinated participants compared with  
401 BNT162b2 recipients (Figure 4A), in line with the ELISpot findings. T cell function  
402 was similar between the two BNT162b2 groups, and there was less IL-2 and TNF  
403 made by the AZD1222 group (Figure 4A). These differences evened out in the hybrid  
404 immunity group. CD8<sup>+</sup> T cells made a substantial fraction of the IFN $\gamma$ , at least half on  
405 average (Figure 4B), with a trend to more in the AZD1222 group, as known for  
406 chimpanzee adenovirus vectored vaccines (Barnes et al., 2012). Very little IL-2 was  
407 made by CD8<sup>+</sup> T cells; the overwhelming majority of the IL-2 response came from  
408 CD4<sup>+</sup> T cells on a per individual basis, irrespective of vaccination regimen (Figure  
409 4C). All groups of participants made polyfunctional T cell responses, which we  
410 defined as IFN $\gamma$ /IL-2/TNF triple-positive cells (Figure 4D). There were no differences  
411 between vaccine regimens in those with hybrid immunity, who uniformly had  
412 polyfunctional responses detectable.

413

414 *CD4+ and CD8+ proliferation responses to SARS-CoV2 spike are higher in*  
415 *previously infected participants*

416 We also assessed cellular responses to SARS-CoV2 using T cell proliferation, a  
417 measure more biased towards central memory responses than IFN $\gamma$  assays. T cell  
418 proliferation to spike S1 and S2 peptide pools was higher in previously infected  
419 AZD1222 vaccinated and the short interval BNT162b2 group compared to naïve  
420 individuals with a 3-8 fold increase in the median responses of CD4<sup>+</sup> and CD8<sup>+</sup> T  
421 cells respectively (Figure 5A, B and D), thus confirming the enduring increase in  
422 cellular memory conferred by infection combined with vaccination. As expected,  
423 responses to M and N were absent in the majority of naïve individuals (Figure 5C, E)  
424 with only one sample per vaccination regimen showing slightly elevated CD4<sup>+</sup> T cell  
425 proliferation (3-11%) which was not explained by N seroconversion (Figure 5C).  
426 Differences between vaccination regimens were only apparent in the BNT162b2  
427 vaccinated hybrid immunity groups with significantly increased CD8 responses to S1,  
428 S2 and M in the short compared to the long interval.

429

430 *The antibody response to SARS-CoV-2 broadens after the third vaccine dose*  
431 *including enhanced neutralisation activity against omicron BA.1*  
432 Despite the differences between the naïve vaccine groups in binding antibody 6  
433 months after the second dose (Figure 2B), there was no significant difference in  
434 neutralisation capacity of sera from these participants against the ancestral Victoria  
435 strain (Figure 6A). Neutralisation titres were lower against delta and lower still  
436 against omicron BA.1 compared with Victoria, as previously described (Dejnirattisai  
437 et al., 2022; Schmidt et al., 2021). The BNT162b2 long interval group had higher  
438 neutralising titres against delta than the short interval group, as they did 28 days  
439 after the second dose (Payne et al., 2021a). Using a surrogate neutralisation assay  
440 on the MSD platform, which measures inhibition of spike-ACE2 binding, we  
441 measured neutralisation of a wider range of variants. We also observed differences  
442 with the BNT162b2 long interval group having higher antibody titres than the other  
443 groups (Figure 6B). Although there was a trend for higher titres in the BNT162b2  
444 short group compared to the AZD1222 group, this did not reach significance. The  
445 surrogate neutralisation assay showed a good correlation with the live virus focus  
446 reduction neutralisation assay for Victoria, delta and omicron variants  
447 (Supplementary Figure S5).

448  
449 After the third dose of vaccine, neutralisation capacity against both the delta and  
450 omicron BA.1 variants increased. Our previous report in this cohort demonstrated  
451 that the neutralisation of omicron BA.1 was significantly higher 28 days after three  
452 doses of BNT162b2 compared to 28 days after 2 doses (Dejnirattisai et al., 2022).  
453 No differences were observed between vaccine groups after the third dose (Figure  
454 6C). These differences also evened out in the ACE2 inhibition assay, though there  
455 was some saturation of the assay (Figure 6D). Therefore, although the overall level  
456 of binding antibody increased minimally (only in the naïve group) between 28 days  
457 after the second and 28 days after the third dose (Figure 3B), the neutralisation  
458 capacity of the antibody response broadened, and the gap between groups closed  
459 (Figure 6E). Thus, we observed a higher quality of response after the third dose,  
460 paralleling what has been seen for clinical effectiveness of a booster dose against  
461 omicron.

462  
463 In a smaller subset of naïve participants, we extended these analyses to BA.2 and  
464 BA.3 (for MSD binding and ACE2 inhibition), 6 months post dose 2 and one month  
465 post dose 3. In order to determine the lasting effects of the booster dose on omicron  
466 variants post dose 3, we studied a further 115 participants for IgG binding to omicron  
467 variants, and 45 participants for live virus neutralisation to omicron BA.1, BA.2 and  
468 BA.5 6 months post dose 3. These assays showed that IgG binding to omicron BA.1,  
469 2 and 3 spike was lower than that for the ancestral strain but persisted well 6 months  
470 after the third dose (Figure 7A-C), including binding to BA.4/5 which we measured at  
471 this time point. ACE2 inhibition by antibody was reduced for omicron BA.1-3, and  
472 ancestral and omicron responses waned (Figure 7D-F). However, the spread of  
473 responses at 6 months post dose 3 was wide, and by this point 11 of the 21

474 participants had contracted omicron infections (Figure 7F). Virus neutralisation for  
475 BA.1, BA.2 and BA.5 showed similar levels of neutralisation for BA.1 and BA.2, and  
476 a slight drop for BA.5 (Figure 7G). These responses waned significantly by 6  
477 months, but in the subgroup of 11 people who became infected with between 1 and  
478 6 months post dose 3 responses were significantly higher to omicron variants, but  
479 not to the ancestral virus (Figure 7G). Neutralisation responses correlated with ACE2  
480 inhibition for most participants (Supplementary Figure S5D-I), with some evidence of  
481 saturation of the ACE2 assay. Importantly, overall, we detected less waning 6  
482 months after the third dose than at the same time point after the second dose.

483

484 *Cross reactive T and B cell responses to the omicron variant are preserved*  
485 *compared with the ancestral strain (Victoria) after second and third vaccine doses*  
486 We investigated the effect of the third vaccine dose on T cell and B cell responses to  
487 omicron variants, in recognition of reduced vaccine effectiveness against infection  
488 with omicron but preservation of protection against severe disease. First, we tested  
489 responses to omicron BA.1 at 6 months post dose 2, similar to the situation for many  
490 people when omicron first appeared in the UK in November 2021. Unlike neutralising  
491 antibody responses, which were much lower for omicron BA.1 6 months after the  
492 second dose (Figure 6A), and lower but with the gap narrowed after the third dose  
493 (Figure 6C), T cell and B cell ELISpot responses were much less impacted. Using  
494 flow cytometry in the same participants in whom we studied multiple cytokine  
495 responses to spike, we did not detect any differences in the functionality of CD4 or  
496 CD8 T cell responses to omicron BA.1 at 6 months post dose 2 (Figure 8A and B),  
497 although the total proportion of the IFN $\gamma$  response in CD4<sup>+</sup> cells dropped slightly  
498 (Figure S6A).

499

500 Using the more sensitive IFN $\gamma$  ELISpot assay, the proportion of ancestral SARS-  
501 CoV-2 T cell responses that were relatively preserved for omicron BA.1 on a per  
502 individual basis was very high 6 months after the second dose (median 94%, IQR  
503 75-110), and one month after a third dose, (median 90%, IQR 70-104), although the  
504 difference between ancestral strain and omicron was significant by Wilcoxon  
505 matched pairs signed rank test (Figure 8C and D). Analysis of T cell ELISpot  
506 responses comparing only the peptides impacted by mutations did reveal a drop  
507 (Figure 8E, median 53%, IQR 22 - 75), but this was not enough to have an impact on  
508 the T cell response for all of spike. We extended this analysis at 6 months post dose  
509 3 for 46 hybrid immune and 28 naïve participants. We tested ancestral SARS-CoV-2  
510 spike peptides alongside those from omicron BA.1, BA.2 and BA.4/5 (Figure 8F). At  
511 this point, there was no difference detected between the T cell response to any  
512 omicron variant in either group by 6 months post third vaccine dose.

513

514 For B cells, responses to omicron BA.1 were lower compared with the ancestral  
515 Victoria strain one month after the second dose (median 59% omicron relative to  
516 ancestral SARS-CoV-2, IQR 56-67,  $p=0.0005$ )(Figure 8G), 6 months after the  
517 second dose (median 57% IQR 45-64,  $p<0.0001$ )(Figure 8H) and one month after a

518 third dose, (median 69% IQR 58-78,  $p < 0.0001$ ) (Figure 8I). This still represents a  
519 relative preservation of B cell immunity, compared with the absolute loss of  
520 neutralising antibodies to omicron after two vaccines (Figure 6A and C).

521

522 We also measured the effect of omicron on proliferative responses of T cells in some  
523 participants. No changes were observed for  $CD4^+$  and  $CD8^+$  T cell proliferation in the  
524 naïve group, though numbers of naïve participants were limited (Supplementary  
525 Figure S6B and D). In the hybrid immunity group, we observed a significant but  
526 modest drop in the proliferative response of  $CD4^+$  and  $CD8^+$  T cells to omicron BA.1  
527 spike S2 (Figure S6C,  $p = 0.0115$ ) and S1 pool (Figure S6E,  $p = 0.034$ ) respectively  
528 when compared to ancestral spike. Overall, T and B cell responses to the omicron  
529 BA.1 variant were well preserved, compared with antibody responses.

530

## 531 **DISCUSSION**

532

533 Our study reports robust immunity to SARS-CoV-2 spike including to omicron  
534 subvariants for all three primary vaccine regimens - BNT162b2 with a short (3-4  
535 week) dosing interval, BNT162b2 with a long (6-17 week) dosing interval, and  
536 AZD1222 – following boosting with an mRNA vaccine. Over the course of the  
537 COVID-19 pandemic, vaccines have significantly reduced the link between the  
538 number of infections with SARS-CoV-2, and the numbers of hospital admissions and  
539 deaths due to COVID-19. Although there has been continual evolution of viral  
540 variants, which have evaded the antibody response to varying degrees (Harvey et  
541 al., 2021), vaccines have retained more effectiveness against severe disease than  
542 against overall infection (Andrews et al., 2022; Tartof et al., 2022; UK Health Security  
543 Agency, 2022). Emerging evidence implicates T cells as one potential mechanism  
544 for this protection, perhaps in addition to non-neutralising antibody functions (Bartsch  
545 Yannic et al.; Kaplonek et al., 2022b; Molodtsov et al., 2022; Scurr et al., 2022). The  
546 presence of both T cell and antibody responses gives the greatest protection from  
547 infection (Molodtsov et al., 2022) and from death in severe disease (Rydzynski  
548 Moderbacher et al., 2020), an observation that is also supported by studies in a  
549 macaque model (McMahan et al., 2021).

550

551 Here, in a cohort of participants which overlaps with the SIREN study - in which  
552 vaccine effectiveness has been shown (Hall et al., 2022), we have observed that  
553 responses after a third dose of COVID vaccine have different dynamics: binding and  
554 neutralising antibodies wane over the 6 months following the second dose, whereas  
555 B and T cell ELISpot responses wane much less over that interval. At 6 months post  
556 second dose, T cells secrete multiple cytokines and proliferate, indicating a broad  
557 range of memory function is retained by these cells. In addition, T cell responses are  
558 higher 6 months after vaccination in uninfected participants than they were in  
559 unvaccinated HCW 6 months after wave 1 infection in 2020, in a previous study of  
560 this cohort, (Tomic et al., 2022). Our findings are similar to those of Maringer et al.  
561 who also found that T cell responses were preserved more than antibody responses

562 between the primary course and booster vaccination (Maringer et al., 2022),  
563 although we also found a benefit with the third dose, likely due to increased power  
564 from a much larger sample size.

565

566 The third vaccine dose boosted all responses from their nadir post dose 2. The  
567 relative magnitude of the T cell boost was smaller compared to the antibody boost  
568 but T cell responses had not waned to the same degree prior to the third dose. The  
569 third vaccine dose led to peak T cell levels which were higher than their previous  
570 peak one-month post second dose. In contrast, the boost to binding antibody  
571 response achieved by the third dose did not exceed the previous peak achieved post  
572 dose 2. Interestingly, although a third dose of vaccine did not achieve higher peak  
573 binding antibody levels, the neutralising capacity of the antibody response was much  
574 greater post dose 3 compared to post dose 2 – replicating earlier observations  
575 (Dejnirattisai et al., 2022). We observed that the B cell response also declined less in  
576 the 6 months after second vaccination than did the neutralising antibody response,  
577 and this implies many of these cells make antibody which binds, but does not  
578 neutralise, the virus.

579

580 With each successive vaccine dose, and up to one month after the third vaccine  
581 dose, participants who had been naturally infected with SARS-CoV-2 had their  
582 antibody and T cell responses boosted and the absolute values achieved were  
583 consistently higher than those who had not been naturally infected. These  
584 observations are particularly important when evaluating the relative benefit of a third  
585 vaccine dose which we demonstrate achieved statistically significant boosting effects  
586 even in the presence of hybrid immunity. These differences finally evened out by 6  
587 months after the third dose. The ex-vivo immunogenicity benefits of hybrid immunity  
588 demonstrated here align with evidence of the enhanced clinical effectiveness of  
589 vaccination in the presence of hybrid immunity (Hall et al., 2022). Superior vaccine  
590 effectiveness has also been observed against omicron BA.1, BA.2 and BA.4/5  
591 infections in those with hybrid immunity, compared with vaccination or infection alone  
592 (Altarawneh et al., 2022; Wei et al., 2022a). A recent systematic review comparing a  
593 range of estimates of protection from previous infection, vaccination and hybrid  
594 immunity has also found that hybrid immunity provides the greatest and most  
595 sustained protection (Bobrovitz et al., 2022).

596

597 We could also still detect an influence of the dose interval of BNT162b2 vaccine at 6  
598 months after second vaccination. However, after the third vaccine dose, these  
599 differences had largely evened out and were no longer significant between the  
600 groups. T cell and antibody responses to spike were lower 6 months after primary  
601 vaccination course for AZD1222 compared to either BNT162b2 dosing regimen.  
602 These findings are compatible with previous reports for antibodies (Wall et al., 2021;  
603 Ward et al., 2022) and lower vaccine effectiveness against infection (UK Health  
604 Security Agency, 2022), although vaccine effectiveness against hospitalisation has  
605 been well preserved. After the AZD1222-primed recipients received a heterologous

606 boost with mRNA vaccine, robust and similar cellular and antibody immunity  
607 including against omicron BA.1 variant was seen for all three regimens studied. We  
608 detected a possible influence of male sex on reducing T cell responses to a third  
609 dose of mRNA vaccine in people who had received a primary course of AZD1222  
610 vaccine. However, this finding was based on a small number of participants so must  
611 be viewed with caution. The larger parent SIREN study would have greater potential  
612 to answer this question definitively, though the public health relevance of this  
613 observation is diminishing over time.

614

615 The third dose gave a broad immune response which could recognise all the variants  
616 tested. This included neutralisation of the omicron BA.1, BA.2 and BA.5 lineages.  
617 The few participants who were followed out to 6 months post dose 3 and had an  
618 omicron infection (11 participants) increased their neutralising antibody responses to  
619 omicron and not to Victoria, providing no evidence of immune imprinting (or antigenic  
620 sin) as has been recently suggested to occur with omicron (Reynolds et al., 2022).  
621 More recent population level evidence from Denmark and the UK suggests that  
622 omicron BA.1 or BA.2 infection in combination with vaccination is more protective  
623 against omicron BA.5 than alpha or delta infection (Hansen et al., 2022; Wei et al.,  
624 2022a). This may be due to waning immunity, antigenic difference, or both, rather  
625 than imprinting. We have not tested the effect of hybrid immunity on subsequent  
626 responses to omicron; such work is ongoing. However, we found no evidence of  
627 antigenic sin for responses after omicron infections, which were larger than the  
628 corresponding increase in antibody to the ancestral vaccine virus. T cell responses  
629 were less impacted by viral variants than antibodies, likely due to the wider range of  
630 epitopes available to T cells compared with antibodies, where protective responses  
631 are more focussed. Our findings are in line with those of others, who have also  
632 observed that antibodies decline more rapidly than T cell responses (Zhang et al.,  
633 2022). We found that T cell responses after the third dose were durable out to 6  
634 months post dose, and that at this point, overall, ancestral and omicron strains were  
635 recognised equally well.

636

637 Our study has a number of limitations. (i) As with other HCW studies, our cohort has  
638 a female majority and is predominantly in people reporting white ethnicity. We have  
639 not observed any impact of sex or ethnicity in this study or our previous reports  
640 (Angyal et al., 2021; Payne et al., 2021a). (ii) Our longitudinal cohort does not  
641 include never-vaccinated participants, because all the HCWs engaged with our  
642 studies across six sites took up vaccination. However, we have been able to  
643 compare responses 6 months after vaccination (in 2021) with historical data using  
644 the same assay in a subset of the same cohort in 2020, 6 months after wave 1  
645 (ancestral strain) infection before vaccine were available (Tomic et al., 2022) and  
646 demonstrate that vaccine-induced responses in infection-naïve HCWs are higher  
647 than infection-induced responses. (iii) We were not able to perform all assays on all  
648 participants at all timepoints, due to lack of sample availability, missed follow up  
649 visits, and/or laboratory capacity. This means that not all our data are longitudinal,



650 though many are. To account for this, we have used unpaired testing in all our  
651 comparisons. (iv) We only performed neutralising antibody measurements on naïve  
652 participants due to the labour intensity and interpretation requiring matching with  
653 infecting variant strain and this information was limited. (v) We defined hybrid  
654 immunity in participants as previously testing PCR positive for SARS-CoV-2, or  
655 seroconversion to anti-N positivity during the study. However, some of the group  
656 labelled as naïve could have been exposed to SARS-CoV-2, because up to 60% of  
657 vaccinated people may not develop anti-N antibody, and the N sequence differs  
658 between variants (Follmann et al., 2022; Whitaker et al., 2021). As time went on, the  
659 N antibody levels rose in our naïve participants, even though many remained below  
660 the assay threshold for a positive N response. As hybrid immunity evolves in the  
661 population it will become increasingly difficult to define the shrinking group of people  
662 who have never been infected with SARS-CoV-2. (vi) For people with vaccine  
663 breakthrough infections since the second vaccine dose, infecting sequence data was  
664 not always available. However, we know that the majority of this report covers a  
665 period in time when delta was the predominant variant, with 68% and 88% of the  
666 sampling complete for this study by 1<sup>st</sup> December 2021 and 1<sup>st</sup> January 2022  
667 respectively. (vii) Finally, we have not addressed mucosal immunity in this report,  
668 this is the subject of ongoing work. Antibody can be readily detected in the mucosa  
669 post infection with SARS-CoV-2 (Fröberg et al., 2021). Cellular and antibody  
670 responses have been also detected in the mucosa after COVID vaccination (Sano et  
671 al., 2022; Ssemaganda et al., 2022), but at low levels and their role in protection  
672 remains unclear.

673

674 In summary, we have observed that SARS-CoV-2 specific cellular immune  
675 responses are better maintained compared to antibodies in the 6 months following  
676 the second dose of COVID-19 vaccine. The third dose of vaccine confers a  
677 measurable benefit to these responses irrespective of the primary course, including  
678 in people who have previously been infected (“hybrid immunity”), who therefore may  
679 also stand to benefit from a third dose. The third dose also induces better antibody  
680 recognition of SARS-CoV-2 variants, including omicron BA.1. Despite public concern  
681 about loss of immunity over time post infection and/or vaccines, we find ample  
682 evidence of strong and durable immunity and memory responses that are likely to  
683 sustain protection against severe COVID-19 long term. Further booster vaccinations  
684 are likely to be most beneficial for preventing severe disease in the clinically  
685 vulnerable, and may lead to a reduction in hospitalisation rates. People with immune  
686 compromise are now receiving fourth or even fifth vaccine doses in UK and other  
687 countries, and parallel studies of durability of immunity in such populations are  
688 needed. The role of further booster vaccines for HCWs requires onward longitudinal  
689 follow-up of this cohort and others, but prevention of infection in HCWs continues to  
690 be desirable to minimise infection-related absence, nosocomial transmission and  
691 risks of long COVID (Antonelli et al., 2022). Our findings allow establishment of the  
692 dynamics of the immune response post infection and vaccination in a healthy  
693 population of working age, which can then be used as a benchmark for evaluating

694 immunity in vulnerable groups, and provides the first glimpse of evolving “hybrid  
695 immunity” driven by ongoing viral exposure in vaccinated populations.

696

## 697 **METHODS**

698

### 699 *Study design and sample collection*

700 In this prospective, observational, cohort study, participants were recruited into the  
701 PITCH study from across six centres (Birmingham, Cambridge, Liverpool,  
702 Newcastle, Oxford and Sheffield). Individuals consenting to participate were  
703 recruited by word of mouth, hospital e-mail communications and from hospital-based  
704 staff screening programmes for SARS-CoV-2, including HCWs enrolled in the  
705 national SIREN study at three sites (Liverpool, Newcastle and Sheffield). Eligible  
706 participants were adults aged 18 or over, and currently working as an HCW,  
707 including allied support and laboratory staff, or were volunteers linked to the hospital.  
708 The majority of participants were sampled for previous reports in this PITCH cohort  
709 ([Angyal et al., 2021](#); [Ogbe et al., 2021](#); [Payne et al., 2021a](#); [Skelly et al., 2021](#)).

710 Participants were sampled for the current study between 4 January 2021 and 15  
711 February 2022, with the majority of the sampling complete before the omicron BA.1  
712 variant emerged in the UK (68% of sampling was prior to December 2021 and 88%  
713 was prior to January 2022).

714

715 Participants had received one of three vaccine regimens: “Short” - two doses of  
716 BNT162b2 (Pfizer/BioNTech) administered with the manufacturer’s licenced dosing  
717 interval (median 24 days, IQR 21-27); “Long” - two doses of BNT162b2  
718 (Pfizer/BioNTech) administered with an extended dosing interval (median 71 days,  
719 IQR 66-78); and “AZ” - two doses of AZD1222 (Oxford/AstraZeneca), administered a  
720 median 74 days (IQR 65-78) apart. All participants then received a third “booster”  
721 dose of BNT162b2, a median of 207 days, (IQR 191-233) days after the second  
722 dose, regardless of primary vaccine regimen. Participants underwent phlebotomy for  
723 assessment of immune responses one (median 28 days, IQR 26-32) and six  
724 (median 185 days, IQR 173-200) months after the second dose of vaccine, and one  
725 month after the third dose of vaccine (median 31 days, IQR 28-37). Clinical  
726 information including BNT162b2 and AZD1222 vaccination dates, date of any SARS-  
727 CoV-2 infection (either prior to vaccination or during the study) defined by a positive  
728 PCR test and/or detection of antibodies to spike or nucleocapsid protein, presence or  
729 absence of symptoms, time between symptom onset and sampling, age, sex and  
730 ethnicity of participant was recorded. Key information on demographics and vaccine  
731 dose intervals is shown in Table 1.

732

733 Participants were considered to be SARS-CoV-2 exposed if they had ever been PCR  
734 or lateral flow device positive for SARS-CoV-2, irrespective of symptoms. In addition,  
735 participants were considered exposed to SARS-CoV-2 if they seroconverted with N  
736 antibody on the mesoscale discovery (MSD) assay. N seroconversion was defined  
737 as an N antibody level over the cut-off threshold of 3874 previously defined using

738 pre-pandemic samples (Payne et al., 2021b), and at least a 2-fold increase over the  
739 baseline value. Participants who did not meet any of these criteria were considered  
740 to be infection-naïve.

741

742 PITCH is a sub-study of the SIREN study, which was approved by the Berkshire  
743 Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC  
744 reference 20/SC/0230), with PITCH recognised as a sub-study on 2 December 2020.  
745 SIREN is registered with ISRCTN (Trial ID:252 ISRCTN11041050). Some  
746 participants were recruited under aligned study protocols. In Birmingham participants  
747 were recruited under the Determining the immune response to SARS-CoV-2  
748 infection in convalescent health care workers (COCO) study (IRAS ID: 282525). In  
749 Liverpool some participants were recruited under the “Human immune responses to  
750 acute virus infections” Study (16/NW/0170), approved by North West - Liverpool  
751 Central Research Ethics Committee on 8 March 2016, and amended on 14th  
752 September 2020 and 4th May 2021. In Oxford, participants were recruited under the  
753 GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at  
754 Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016,  
755 which has been amended for this purpose on 8 June 2020. In Sheffield, participants  
756 were recruited under the Observational Biobanking study STHObs (18/YH/0441),  
757 which was amended for this study on 10 September 2020. We also included some  
758 participants from Cambridge from a study approved by the National Research Ethics  
759 Committee and Health Research Authority (East of England – Cambridge Research  
760 Ethics Committee (SCORPIO study, SARS-CoV-2 vaccination response in obesity  
761 amendment of “NIHR BioResource” 17/EE/0025).The study was conducted in  
762 compliance with all relevant ethical regulations for work with human participants, and  
763 according to the principles of the Declaration of Helsinki (2008) and the International  
764 Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines.  
765 Written informed consent was obtained for all participants enrolled in the study.

766

767 Peripheral blood mononuclear cells (PBMCs), plasma and serum were separated  
768 and cryopreserved. Some of the immune response data from one month after the  
769 second dose has been previously reported (Payne et al., 2021a), as has some of the  
770 neutralising antibody data for HCWs receiving a short dosing interval for BNT162b2  
771 (Dejnirattisai et al., 2022). The study size was selected because this number was  
772 feasible for the six clinical and laboratory sites to study, and consistent with our track  
773 record of significant findings at this scale.

774

#### 775 *Meso Scale Discovery (MSD) IgG binding assay*

776 IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and seasonal  
777 coronaviruses were measured using a multiplexed MSD immunoassay: The V-PLEX  
778 COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale  
779 Discovery, Rockville, MD USA. A MULTI-SPOT<sup>®</sup> 96-well, 10 spot plate was coated  
780 with three SARS CoV-2 antigens (Spike (S), Receptor-Binding Domain (RBD),  
781 Nucleoprotein (N)), SARS-CoV-1 and MERS-CoV spike trimers, spike proteins from

782 seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-  
783 NL63, and bovine serum albumin (negative control). Antigens were spotted at  
784 200–400 µg/mL (MSD<sup>®</sup> Coronavirus Plate 3). Multiplex MSD assays were performed  
785 as per the manufacturer's instructions. To measure IgG antibodies, 96-well plates  
786 were blocked with MSD Blocker A for 30 minutes. Following washing with washing  
787 buffer, samples diluted 1:1,000-30,000 in diluent buffer, MSD standard and undiluted  
788 internal MSD controls, were added to the wells. After 2-hour incubation and a  
789 washing step, detection antibody (MSD SULFO-TAG<sup>™</sup> anti-human IgG antibody,  
790 1/200) was added. Following washing, MSD GOLD<sup>™</sup> read buffer B was added and  
791 plates were read using a MESO<sup>®</sup> SECTOR S 600 reader. The standard curve was  
792 established by fitting the signals from the standard using a 4-parameter logistic  
793 model. Concentrations of samples were determined from the  
794 electrochemiluminescence signals by back-fitting to the standard curve and  
795 multiplying by the dilution factor. Concentrations are expressed in Arbitrary Units/ml  
796 (AU/ml). Cut-offs were determined for each SARS-CoV-2 antigen (S, RBD and N)  
797 based on the mean concentrations measured in 103 pre-pandemic sera + 3  
798 Standard Deviations. Cut-offs were: S, 1160 AU/ml; RBD, 1169 AU/ml; and N, 3874  
799 AU/ml.

800

#### 801 *MSD ACE2 inhibition assay*

802 The V-PLEX SARS-CoV-2 Panel 23 (ACE2) Kit, from MSD, Rockville, MD, a  
803 multiplexed MSD immunoassay, was also used to measure the ability of human sera  
804 to inhibit ACE2 binding to SARS-CoV-2 spike antigens including B (Victoria),  
805 B.1.1.7/alpha, B.1.351/beta P.1/gamma, B.1.617.2/delta or B.1.1.529; BA.1/omicron  
806 BA.1). A MULTI-SPOT 96-well, 10 spot plate was coated with SARS-CoV-2 spike  
807 antigens including these ones above-mentioned. Multiplex MSD Assays were  
808 performed as per manufacturer's instructions. To measure ACE2 inhibition, 96-well  
809 plates were blocked with MSD Blocker for 30 minutes. Plates were then washed in  
810 MSD washing buffer, and samples were diluted 1:10 – 1:100 in diluent buffer.  
811 Neutralizing activity was determined by measuring the presence of antibodies able to  
812 block the binding of ACE2 to SARS-CoV-2 spike proteins from Victoria spike,  
813 B.1.1.7/alpha, B.1.617.2/delta, B.1.351/beta, P.1/gamma and B.1.1.529;  
814 BA.1/omicron BA.1 and was expressed as percentage of ACE2 inhibition in  
815 comparison to the blanks on the same plate. Furthermore, internal controls and the  
816 WHO SARS-CoV-2 Immunoglobulin international standard (NIBSC 20/136) were  
817 added to each plate. After a 1-hour incubation, recombinant human ACE2-SULFO-  
818 TAG was added to all wells. After a further 1-hour, plates were washed and MSD  
819 GOLD Read Buffer B was added, plates were then immediately read using a MESO  
820 SECTOR S 600 Reader.

821

#### 822 *Focus Reduction Neutralisation Assay (FRNT)*

823 The neutralisation potential of antibodies (Ab) was measured using a Focus  
824 Reduction Neutralisation Test (FRNT), where the reduction in the number of the  
825 infected foci is compared to a negative control well without antibody. Briefly, serially

826 diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria or P.1 and  
827 incubated for 1 hr at 37°C. The mixtures were then transferred to 96-well, cell culture-  
828 treated, flat-bottom microplates containing confluent Vero cell monolayers in  
829 duplicate and incubated for a further 2 hr followed by the addition of 1.5% semi-solid  
830 carboxymethyl cellulose (Sigma) overlay medium to each well to limit virus diffusion.  
831 A focus forming assay was then performed by staining Vero cells with human anti-  
832 nucleocapsid monoclonal Ab (mAb206) followed by peroxidase-conjugated goat anti-  
833 human IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per  
834 well in the absence of antibodies, were visualized by adding TrueBlue Peroxidase  
835 Substrate (Insight Biotechnology). Virus-infected cell foci were counted on the  
836 classic AID ELISpot reader using AID ELISpot software. The percentage of focus  
837 reduction was calculated and IC50 was determined using the probit program from  
838 the SPSS package. In order to reduce confounding arising from exposure to different  
839 SARS-CoV-2 variants, these experiments were conducted only on participants who  
840 were naive at the time of sampling 6-months post second vaccine dose, as defined  
841 by no history of positive PCR or lateral flow test for SARS-CoV-2, and no anti-N IgG  
842 seroconversion during the study.

843

#### 844 *T cell interferon-gamma (IFN $\gamma$ ) ELISpot Assay*

845 The PITCH ELISpot Standard Operating Procedure has been published previously  
846 (Angyal et al., 2021). Interferon-gamma (IFN $\gamma$ ) ELISpot assays were set up from  
847 cryopreserved PBMCs using the Human IFN $\gamma$  ELISpot Basic kit (Mabtech 3420-2A).  
848 A single protocol was agreed across the centres as previously published (Angyal et  
849 al., 2021) and available on the PITCH website (<http://www.pitch-study.org/>).  
850 In brief, PBMCs were thawed and rested for 3-6 hours in R10 media: RPMI 1640  
851 (Sigma) supplemented with 10% (v/v) Fetal Bovine Serum (Sigma), 2mM L-  
852 Glutamine (Sigma) and 1mM Penicillin/Streptomycin (Sigma) in a humidified  
853 incubator at 37°C, 5% CO<sub>2</sub>, prior to stimulation with peptides. PBMCs were then  
854 plated in duplicate or triplicate at 200,000 cells/well in a MultiScreen-IP filter plate  
855 (Millipore, MAIPS4510) previously coated with capture antibody (clone 1-D1K) and  
856 blocked with R10. PBMCs were then stimulated with overlapping peptide pools (18-  
857 mers with 10 amino acid overlap, Mimotopes) representing the spike (S), Membrane  
858 (M) or nucleocapsid (N) SARS-CoV-2 proteins at a final concentration of 2  $\mu$ g/ml for  
859 16 to 18 hours in a humidified incubator at 37°C, 5% CO<sub>2</sub>. For selected individuals,  
860 pools representing spike protein of the Omicron (BA.1) variant were included. Pools  
861 consisting of CMV, EBV and influenza peptides at a final concentration of 2  $\mu$ g/ml  
862 (CEF; Proimmune) and concanavalin A or phytohemagglutinin L (PHA-L, Sigma)  
863 were used as positive controls. DMSO was used as the negative control at an  
864 equivalent concentration to the peptides. After the incubation period as well as all  
865 subsequent steps wells were washed with PBS/0.05% (v/v) Tween20 (Sigma). Wells  
866 were incubated with biotinylated detection antibody (clone 7-B6-1) followed by  
867 incubation with the ELISpot Basic kit streptavidin-ALP. Finally colour development  
868 was carried out using the 1-step NBT/BCIP substrate solution (Thermo Scientific) for  
869 5 minutes at RT. Colour development was stopped by washing the wells with tap

870 water. Air dried plates were scanned and analysed with either the AID Classic  
871 ELISpot reader (software version 8.0, Autoimmune Diagnostika GmbH, Germany) or  
872 the ImmunoSpot® S6 Alfa Analyser (Cellular Technology Limited LLC, Germany).  
873 Antigen-specific responses were quantified by subtracting the mean spots of the  
874 negative control wells from the test wells and the results were expressed as spot-  
875 forming units (SFU)/10<sup>6</sup> PBMCs. Samples with a mean spot value greater than 50  
876 spots in the negative control wells were excluded from the analysis.

877

878 For comparison of responses to omicron BA.1 we firstly compared responses to 178  
879 peptides spanning all of spike (S1 and S2) for the ancestral (wild type) and the  
880 omicron BA.1 variant, then secondly, we compared responses to the 51 peptides  
881 representing the regions of spike with mutations in omicron BA.1, again comparing  
882 ancestral and omicron BA.1. To reduce the disproportionate impact of background  
883 noise, samples with a total response to ancestral spike of <33 SFU/10<sup>6</sup> PBMCs were  
884 excluded from analysis, with this cut off threshold calculated as the mean + 2  
885 standard deviations of the DMSO wells across all experiments in the study. The % of  
886 the T cell response to ancestral strain that was preserved against omicron BA.1 was  
887 calculated for each paired sample then expressed as the median and IQR for the  
888 group.

889

#### 890 *Memory B cell Fluorospot assay*

891 Cryopreserved PBMCs were thawed and cultured for 72 hours with polyclonal  
892 stimulation containing 1 µg/ml R848 and 10 ng/ml IL-2 from the Human memory B  
893 cell stimpack (Mabtech). Using the Human IgA/IgG FluoroSpotFLEX kit (Mabtech),  
894 stimulated PBMCs were then added at 2x10<sup>5</sup> cells/well to fluorospot plates coated  
895 with 10 µg/ml Sars-CoV-2 spike glycoprotein diluted in PBS. Plates were incubated  
896 for 16 hours in a humidified incubator at 37°C, 5% CO<sub>2</sub> and developed according to  
897 the manufacturer's instructions (Mabtech). Analysis was carried out with AID ELISpot  
898 software 8.0 (Autoimmun Diagnostika). All samples were tested in triplicates and  
899 response was measured as spike- specific spots per million PBMCs with PBS  
900 background subtracted.

901

#### 902 *Intracellular cytokine stimulation assay*

903 In a subset of donors (n=95), selected at random from all three vaccine regimens  
904 and previous SARS-CoV-2 infection, T cell responses were characterised further  
905 using intracellular cytokine staining (ICS) after stimulation with overlapping SARS-  
906 CoV2 peptide pools. In brief, cryopreserved PBMCs were thawed, rested for 4-5  
907 hours in R10 media and then plated at 1x10<sup>6</sup> cells/well in a 96 well U-bottom plate  
908 together with co-stimulatory molecules anti-CD28 and anti-CD49d (both BD). Peptide  
909 pools (spanning ancestral (B.1) spike, omicron BA.1 spike, ancestral membrane (M)  
910 and nucleocapsid (N) proteins) were added at 2 µg/ml final concentration for each  
911 peptide. DMSO (Sigma) was used as the negative control at the equivalent  
912 concentration to the peptides. As a positive control, cells were stimulated with 1x cell  
913 activation cocktail containing phorbol-12-myristate 13-acetate (PMA) at 81µM and

914 ionomycin at 1.3 $\mu$ M final concentration (Biolegend). The cells were then incubated in  
915 a humidified incubator at 37°C, 5% CO<sub>2</sub> for 1 hour before incubating for a further 15  
916 hours in the presence of 5 $\mu$ g/ml Brefeldin A (Biolegend). Flow cytometry staining  
917 was performed as described below.

918

#### 919 *Proliferation assay*

920 T cell proliferation assessed the magnitude of memory responses to SARS-CoV2  
921 spike, M and N protein in the CD4<sup>+</sup> and CD8<sup>+</sup> T cell pool in 73 individuals selected  
922 for the ICS assay, with 27 participants from the BNT162b2 short interval group (16  
923 naïve and 11 with hybrid immunity), 27 participants from the BNT162b2 long interval  
924 group (15 naïve and 12 with hybrid immunity) and 19 participants from the AZD1222  
925 group (8 naïve and 11 with hybrid immunity). CellTrace™ Violet (CTV, Invitrogen)  
926 labelling and stimulation with SARS-CoV-2 peptide pools spanning ancestral spike  
927 (divided into two pools, S1 and S2), omicron (BA.1) spike (S1 and S2), ancestral M  
928 and N protein, as well as a control peptide mix, CEF (1 $\mu$ g/ml per peptide) was  
929 carried out as previously described (Ogbe et al., 2021). Cells were incubated in  
930 RPMI 1640 (Sigma) supplemented with 10% human AB serum (Sigma), 2mM L-  
931 glutamine (Sigma) and 1 mM Penicillin/Streptomycin (Sigma) in a 96 well U-bottom  
932 plate at 250,000 cells per well in single or duplicate depending on cell availability.  
933 DMSO added at the same concentration to SARS-CoV-2 peptides served as  
934 negative control and 2 $\mu$ g/ml PHA-L as positive control. Cells were placed in a  
935 humidified incubator at 37°C, 5% CO<sub>2</sub>. Half a media change was performed on day 4  
936 and cells were harvested for flow cytometry staining on day 7 as described below.  
937 Data were expressed as relative frequency of proliferating cells within single, live  
938 CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells respectively. Background was subtracted from  
939 stimulated samples and samples were excluded due to high background (DMSO  
940 control >2% proliferation in any T cell subset,) or less than 1000 events in the single,  
941 live CD3<sup>+</sup> gate (10 samples in total were excluded). Responses to individual peptide  
942 pools and summed responses to total spike (S1+S2) and M+NP were reported.

943

944

#### 945 *Flow cytometry staining and analysis*

946 Details for antibodies are listed in Supplementary Table 2. All washes and  
947 extracellular staining steps for PBMC were carried out in cell staining buffer  
948 (Biolegend) for ICS samples and PBS for proliferation samples. At the end of the  
949 culture period, PBMCs were washed once and subsequently stained with near-  
950 infrared fixable live/dead stain (Invitrogen) together with a cocktail of fluorochrome-  
951 conjugated primary human-specific antibodies against CD4, CD8, CD14 (all  
952 Biolegend) as well as human Fc blocking reagent (Miltenyi Biotec) for ICS and CD3,  
953 CD4 and CD8 (all Biolegend) for proliferation samples. Cells were stained at 4°C in  
954 the dark for 20 minutes, followed by one wash. Proliferation samples were then fixed  
955 with a 4% formaldehyde solution (Sigma) for 10min at 4°C, washed and stored in  
956 PBS in the fridge for up to one day. ICS samples were fixed and permeabilized in  
957 Cytofix/Cytoperm buffer (BD) for 20 min at 4°C, washed with 1x Perm buffer (BD)

958 once followed by staining with the following primary human-specific antibodies  
959 diluted in Perm buffer: CD3, IFN- $\gamma$ , TNF (all Biolegend), IL-2 (eBioscience) for 20 min  
960 at 4°C followed by one wash in 1x Perm buffer. Cells were stored in cell staining  
961 buffer in the fridge for up to one day. Samples were acquired on a MACSQuant  
962 analyser 10 and X (Miltenyi Biotec) and analysis was performed using FlowJo  
963 software version 10.8.1 (BD Biosciences). Example gating strategies are shown in  
964 Supplementary Figure 1.

965

#### 966 *Statistical analysis*

967 Continuous variables are displayed with median and interquartile range (IQR).  
968 Unpaired comparisons across two groups were performed using the Mann-Whitney  
969 test, and across three groups using the Kruskal-Wallis test with Dunn's multiple  
970 comparisons test. Paired comparisons were performed using the Wilcoxon matched  
971 pairs signed rank test. Two-tailed P values are displayed. Statistical analyses were  
972 done using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria.  
973 URL <https://www.R-project.org/>) using the tidyverse packages (Wickham et al., 2019)  
974 and GraphPad Prism 9.3.1.

975



976 **ACKNOWLEDGEMENTS**

977 We are grateful to all our healthcare worker colleagues who participated in the study.  
978 For the Birmingham participants, the study was carried out at the National Institute  
979 for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility.  
980 Laboratory studies were undertaken by the Clinical Immunology Service, University  
981 of Birmingham.

982

983

984 **AUTHOR CONTRIBUTIONS**

985 Conceptualization, L.T., S.J.D., P.K., T.dS., S.H., V.H., C.J.A.D., R.P.P., A.R., M.C., G.S.;  
986 Methodology, S.J.D., P.K., L.T., S.C.M., B.K., S.L., T.dS., C.J.A.D., A.R., M.C., G.S., C.D.,  
987 N.G., S.H., V.H.; Formal Analysis, B.K., S.C.M., S.J.D., L.T., T.dS., C.D., S.L., D.T.S., W.D.,  
988 A.S.D., S.A., J.D.W. Investigation, B.K., R.P.P., S.L., C.L., W.D., S.A., N.M., S.F., S.A-T.,  
989 S.C.M., T.T., L.M.H., A.A., R.B., A.R.N., S.L.D., E.C.H., L.H.B., P.S., A.C., A.B-W., L.S.R.,  
990 A.L., J.K.T., H.H., I.G., M.P., P.Z., T.A.H.N., J.M.N., P.A., E.P., T.M., I.N., A.H., A.Sh., L.S.,  
991 D.G.W., A.B.; Resources, A.B., L.T., E.B.; Data Curation, S.C.M., A.D.; Writing – Original  
992 Draft, L.T., S.J.D., P.K., Writing – Review & Editing, B.K., S.C.M., S.L., T.dS., S.L.D., S.J.,  
993 D.G.W., C.P.C., K.J., P.C.M., A.J.P., J.M., E.B., A.R., M.C., G.S.; Visualization, S.C.M., S.L.,  
994 B.K., S.A., J.D.W., L.T., S.J.D., Supervision, B.K., C.P.C., K.J., J.F., A.J.P., S.L.R-J.,  
995 J.E.D.T., R.P.P., J.M., E.B., S.H., V.H., C.D., C.J.A.D., A.R., M.C., G.S., T.dS., L.T., P.K.,  
996 S.J.D., Project Administration, A.S.D., Funding Acquisition, P.K., S.J.D., L.T., T.dS.,  
997 C.J.A.D., A.R., S.H., V.H.

998

999

1000 **DECLARATION OF INTERESTS**

1001 This work was funded by the UK Department of Health and Social Care as part of  
1002 the PITCH (Protective Immunity from T cells to Covid-19 in Health workers)  
1003 Consortium, UKRI as part of “Investigation of proven vaccine breakthrough by  
1004 SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN  
1005 consortium & PITCH Plus Pathway” MR/W02067X/1, with contributions from  
1006 UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo  
1007 Family Foundation and The National Institute for Health Research (UKRIDHSC  
1008 COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19-  
1009 RECPLAS).

1010

1011 E.B. and P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA.  
1012 S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.dS is  
1013 funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). RPP  
1014 is funded by a Career Re-entry Fellowship (204721/Z/16/Z). C.J.A.D. is funded by a  
1015 Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z). J.M.  
1016 and G.S. are funded by the Chinese Academy of Medical Sciences (CAMS)  
1017 Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-  
1018 002), Schmidt Futures, the Red Avenue Foundation and the Oak Foundation. The  
1019 Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant  
1020 090532/Z/09/Z). P.C.M. is funded by Wellcome (110110z/15/Z), the Francis Crick

1021 Institute, and the University College London Hospital NIHR Biomedical Research  
1022 Centre. J.E.D.T. is supported by the Medical Research Council (MR/W020564/1)  
1023 and (MC\_UU\_0025/12). L.T. is supported by the Wellcome Trust (grant number  
1024 205228/Z/16/Z), the National Institute for Health Research Health Protection  
1025 Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (EZI)  
1026 (NIHR200907) and the Centre of Excellence in Infectious Diseases Research  
1027 (CEIDR) and the Alder Hey Charity. The HPRU-EZI at University of Liverpool is in  
1028 partnership with UK Health Security Agency (UKHSA), in collaboration with Liverpool  
1029 School of Tropical Medicine and the University of Oxford. D.G.W. is supported by an  
1030 NIHR Advanced Fellowship in Liverpool. M.C., S.L., L.T., and T.T. are supported by  
1031 U.S. Food and Drug Administration Medical Countermeasures Initiative contract  
1032 75F40120C00085. The Sheffield Teaching Hospitals Observational Study of Patients  
1033 with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-  
1034 ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STH-  
1035 ObS Chief Investigator Allan Laurie is supported by a British Heart Foundation  
1036 Senior Basic Science Research fellowship (FS/18/52/33808). We gratefully  
1037 acknowledge financial support from the UK Department of Health and Social Care  
1038 via the Sheffield NIHR Clinical Research Facility award to the Sheffield Teaching  
1039 Hospitals Foundation NHS Trust.

1040

1041 The views expressed are those of the author(s) and not necessarily those of the  
1042 NHS, the NIHR, the Department of Health and Social Care or Public Health England  
1043 or the US Food and Drug Administration.

1044

1045 S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she  
1046 receives a fee. A.J.P. is Chair of UK Dept. Health and Social Care's (DHSC) Joint  
1047 Committee on Vaccination & Immunisation (JCVI), but does not participate in policy  
1048 decisions on COVID-19 vaccines. He was previously a member of the WHO's  
1049 SAGE. The views expressed in this article do not necessarily represent the views of  
1050 DHSC, JCVI, or WHO. AJP is chief investigator on clinical trials of Oxford  
1051 University's COVID-19 vaccine funded by NIHR. Oxford University has entered a  
1052 joint COVID-19 vaccine development partnership with AstraZeneca. G.S. sits on the  
1053 GSK Vaccines Scientific Advisory Board and is a founder member of RQ  
1054 Biotechnology.

1055

1056

1057

1058

1059

1060

1061 **REFERENCES**

1062

1063 Addetia, A., Crawford Katharine, H.D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-  
1064 L., Jerome Keith, R., Bloom Jesse, D., Greninger Alexander, L., and McAdam Alexander, J.  
1065 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a  
1066 Fishery Vessel Outbreak with a High Attack Rate. *Journal of Clinical Microbiology* 58,  
1067 e02107-02120.

1068 Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Yassine, H.M., Al-  
1069 Khatib, H.A., Smatti, M.K., Coyle, P., Al-Kanaani, Z., *et al.* (2022). Effects of Previous  
1070 Infection and Vaccination on Symptomatic Omicron Infections. *New England Journal of*  
1071 *Medicine* 387, 21-34.

1072 Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall,  
1073 M., Groves, N., O'Connell, A.-M., *et al.* (2022). Covid-19 Vaccine Effectiveness against the  
1074 Omicron (B.1.1.529) Variant. *New England Journal of Medicine* 386, 1532-1546.

1075 Angyal, A., Longet, S., Moore, S.C., Payne, R.P., Harding, A., Tipton, T., Rongkard, P., Ali,  
1076 M., Hering, L.M., Meardon, N., *et al.* (2021). T-cell and antibody responses to first BNT162b2  
1077 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a  
1078 multicentre prospective cohort study. *Lancet Microbe*.

1079 Antonelli, M., Penfold, R.S., Merino, J., Sudre, C.H., Molteni, E., Berry, S., Canas, L.S.,  
1080 Graham, M.S., Klaser, K., Modat, M., *et al.* (2022). Risk factors and disease profile of post-  
1081 vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a  
1082 prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases*  
1083 22, 43-55.

1084 Barnes, E., Folgari, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart,  
1085 R., Smith, K., Townsend, R., *et al.* (2012). Novel adenovirus-based vaccines induce broad  
1086 and sustained T cell responses to HCV in man. *Sci Transl Med* 4, 115ra111.

1087 Bartsch Yannic, C., Tong, X., Kang, J., Avendaño María, J., Serrano Eileen, F., García-  
1088 Salum, T., Pardo-Roa, C., Riquelme, A., Cai, Y., Renzi, I., *et al.* Omicron variant Spike-  
1089 specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated  
1090 COVID-19 vaccines. *Science Translational Medicine* 14, eabn9243.

1091 Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M.,  
1092 Premji, Z., Issa, H., *et al.* (2022). Protective effectiveness of prior SARS-CoV-2 infection and  
1093 hybrid immunity against Omicron infection and severe disease: a systematic review and  
1094 meta-regression. *medRxiv*, 2022.2010.2002.22280610.

1095 Carazo, S., Skowronski, D.M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki,  
1096 M., Barkati, S., Fafard, J., Talbot, D., *et al.* (2022). Protection against Omicron re-infection  
1097 conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination.  
1098 *medRxiv*, 2022.2004.2029.22274455.

1099 De Marco, L., D'Orso, S., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Capone, A.,  
1100 Sabatini, A., Guerrero, G., Placido, R., *et al.* (2022). Assessment of T-cell Reactivity to the  
1101 SARS-CoV-2 Omicron Variant by Immunized Individuals. *JAMA Network Open* 5, e2210871-  
1102 e2210871.

1103 Dejnirattisai, W., Huo, J., Zhou, D., Zahradnik, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E.,  
1104 Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., *et al.* (2022). SARS-CoV-2 Omicron-B.1.1.529  
1105 leads to widespread escape from neutralizing antibody responses. *Cell* 185, 467-484 e415.

- 1106 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,  
1107 Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for COVID-  
1108 19 vaccines. *Vaccine* 39, 4423-4428.
- 1109 Ewer, K.J., Barrett, J.R., Belij-Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R.,  
1110 Flaxman, A., Wright, D., Bellamy, D., Bittaye, M., *et al.* (2021). T cell and antibody responses  
1111 induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical  
1112 trial. *Nat Med* 27, 270-278.
- 1113 Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M.,  
1114 Gilbert, S.C., Hirsch, I., *et al.* (2021). Correlates of protection against symptomatic and  
1115 asymptomatic SARS-CoV-2 infection. *Nature Medicine* 27, 2032-2040.
- 1116 Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,  
1117 Desjardins, M., Corey, L., Neuzil, K.M., *et al.* (2022). Antinucleocapsid Antibodies After  
1118 SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-  
1119 1273 COVID-19 Vaccine Efficacy Clinical Trial. *Ann Intern Med*, DOI: 10.7326/M7322-1300.
- 1120 Fröberg, J., Gillard, J., Philipsen, R., Lanke, K., Rust, J., Van Tuijl, D., Teelen, K., Bousema,  
1121 T., Simonetti, E., Van Der Gaast-De Jongh, C.E., *et al.* (2021). SARS-CoV-2 mucosal  
1122 antibody development and persistence and their relation to viral load and COVID-19  
1123 symptoms. *Nature Communications* 12.
- 1124 Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,  
1125 Österborg, A., Bergman, P., *et al.* (2022). Ancestral SARS-CoV-2-specific T cells cross-  
1126 recognize the Omicron variant. *Nature Medicine* 28, 472-476.
- 1127 GeurtsvanKessel Corine, H., Geers, D., Schmitz Katharina, S., Mykytyn Anna, Z., Lamers  
1128 Mart, M., Bogers, S., Scherbeijn, S., Gommers, L., Sablerolles Roos, S.G., Nieuwkoop Nella,  
1129 N., *et al.* (2022). Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in  
1130 COVID-19 vaccine recipients. *Science Immunology* 7, eabo2202.
- 1131 Gilbert, P.B., Montefiori David, C., McDermott Adrian, B., Fong, Y., Benkeser, D., Deng, W.,  
1132 Zhou, H., Houchens Christopher, R., Martins, K., Jayashankar, L., *et al.* (2022). Immune  
1133 correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* 375,  
1134 43-50.
- 1135 Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L., Haas, E.J., Milo,  
1136 R., Alroy-Preis, S., Ash, N., and Huppert, A. (2021). Waning Immunity after the BNT162b2  
1137 Vaccine in Israel. *N Engl J Med* 385, e85.
- 1138 Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,  
1139 Munro, K., Cole, M., *et al.* (2022). Protection against SARS-CoV-2 after Covid-19  
1140 Vaccination and Previous Infection. *New England Journal of Medicine* 386, 1207-1220.
- 1141 Hall, V.J., Foulkes, S., Charlett, A., Atti, A., Monk, E.J.M., Simmons, R., Wellington, E., Cole,  
1142 M.J., Saei, A., Oguti, B., *et al.* (2021a). SARS-CoV-2 infection rates of antibody-positive  
1143 compared with antibody-negative health-care workers in England: a large, multicentre,  
1144 prospective cohort study (SIREN). *Lancet* 397, 1459-1469.
- 1145 Hall, V.J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe,  
1146 J., Gillson, N., Atti, A., *et al.* (2021b). COVID-19 vaccine coverage in health-care workers in  
1147 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a  
1148 prospective, multicentre, cohort study. *Lancet* 397, 1725-1735.

- 1149 Hansen, C.H., Friis, U.F., Bager, P., Stegger, M., Fonager, J., Fomsgaard, A., Gram, M.A.,  
1150 Christiansen, L.E., Ethelberg, S., Legarth, R., *et al.* (2022). Risk of reinfection, vaccine  
1151 protection, and severity of infection with the BA.5 omicron subvariant: a Danish nation-wide  
1152 population-based study. Available at SSRN: .
- 1153 Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M.,  
1154 Ludden, C., Reeve, R., Rambaut, A., Peacock, S.J., *et al.* (2021). SARS-CoV-2 variants,  
1155 spike mutations and immune escape. *Nature Reviews Microbiology* 19, 409-424.
- 1156 Kaplonek, P., Cizmeci, D., Fischinger, S., Collier, A.-r., Suscovich, T., Linde, C., Broge, T.,  
1157 Mann, C., Amanat, F., Dayal, D., *et al.* (2022a). mRNA-1273 and BNT162b2 COVID-19  
1158 vaccines elicit antibodies with differences in Fc-mediated effector functions. *Science*  
1159 *Translational Medicine* 14, eabm2311.
- 1160 Kaplonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y.C., Kang, J., Burke, J.S., Shin, S.A.,  
1161 Dayal, D., Martin, P., Mann, C., *et al.* (2022b). mRNA-1273 vaccine-induced antibodies  
1162 maintain Fc effector functions across SARS-CoV-2 variants of concern. *Immunity* 55, 355-  
1163 365.e354.
- 1164 Kedzierska, K., and Thomas, P.G. (2022). Count on us: T cells in SARS-CoV-2 infection and  
1165 vaccination. *Cell Reports Medicine* 3, 100562.
- 1166 Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele,  
1167 S., Bernstein, M., Karim, F., *et al.* (2022). T cell responses to SARS-CoV-2 spike cross-  
1168 recognize Omicron. *Nature* 603, 488-492.
- 1169 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,  
1170 K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are  
1171 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*  
1172 *Medicine* 27, 1205-1211.
- 1173 Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez, N.D., Conibear, E.,  
1174 Koycheva, A., Davies, M., Tolosa-Wright, M., *et al.* (2022). Cross-reactive memory T cells  
1175 associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nature*  
1176 *Communications* 13, 80.
- 1177 Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S., Sunny, S.-K., Moore, Z., and Zeng,  
1178 D. (2022). Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *New*  
1179 *England Journal of Medicine* 386, 933-941.
- 1180 Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K.,  
1181 Sciacca, M., VanWyk, H., Wu, C., *et al.* (2022). Vaccines elicit highly conserved cellular  
1182 immunity to SARS-CoV-2 Omicron. *Nature* 603, 493-496.
- 1183 Madelon, N., Heikkilä, N., Sabater Royo, I., Fontannaz, P., Breville, G., Lauper, K.,  
1184 Goldstein, R., Grifoni, A., Sette, A., Siegrist, C.-A., *et al.* (2022). Omicron-Specific Cytotoxic  
1185 T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With  
1186 Multiple Sclerosis Treated With Ocrelizumab. *JAMA Neurology*.
- 1187 Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Horber, S., Peter, A., Karbach,  
1188 J., Jager, E., and Walz, J.S. (2022). Durable spike-specific T-cell responses after different  
1189 COVID-19 vaccination regimens are not further enhanced by booster vaccination. *Sci*  
1190 *Immunol*, eadd3899.

- 1191 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,  
1192 Peter, L., Atyeo, C., Zhu, A., *et al.* (2021). Correlates of protection against SARS-CoV-2 in  
1193 rhesus macaques. *Nature* 590, 630-634.
- 1194 Mefsin, Y., Chen, D., Bond, H.S., Lin, Y., Cheung, J.K., Wong, J.Y., Ali, S.T., Lau, E.H.Y.,  
1195 Wu, P., Leung, G.M., *et al.* (2022). Epidemiology of infections with SARS-CoV-2 Omicron  
1196 BA.2 variant in Hong Kong, January-March 2022. medRxiv, 2022.2004.2007.22273595.
- 1197 Molodtsov, I.A., Kegeles, E., Mitin, A.N., Mityaeva, O., Musatova, O.E., Panova, A.E.,  
1198 Pashenkov, M.V., Peshkova, I.O., Alsalloum, A., Asaad, W., *et al.* (2022). Severe Acute  
1199 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in  
1200 Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. *Clinical Infectious  
1201 Diseases* 75, e1-e9.
- 1202 Moore, P.L., Moyo-Gwete, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., Sadoff, J.,  
1203 Le Gars, M., van Roey, G., Crowther, C., *et al.* (2021). Neutralizing antibodies elicited by the  
1204 Ad26.COVS.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite  
1205 protection against severe disease by this variant. bioRxiv, DOI: 2021.2006.2009.447722.
- 1206 Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L.,  
1207 Rumm, A.P., Maruste, R., Kärner, J., *et al.* (2021). Dynamics of antibody response to  
1208 BNT162b2 vaccine after six months: a longitudinal prospective study. *The Lancet Regional  
1209 Health – Europe* 10.
- 1210 Nyberg, T., Ferguson, N.M., Nash, S.G., Webster, H.H., Flaxman, S., Andrews, N., Hinsley,  
1211 W., Bernal, J.L., Kall, M., Bhatt, S., *et al.* (2022). Comparative analysis of the risks of  
1212 hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta  
1213 (B.1.617.2) variants in England: a cohort study. *The Lancet* 399, 1303-1312.
- 1214 Ogbe, A., Kronsteiner, B., Skelly, D.T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter,  
1215 H.D., Ali, M., Ali, S.-E., *et al.* (2021). T cell assays differentiate clinical and subclinical SARS-  
1216 CoV-2 infections from cross-reactive antiviral responses. *Nat Commun* 12, 2055.
- 1217 Otter, A.D., D’Arcangelo, S., Whitaker, H., Hewson, J., Foulkes, S., Atti, A., Cole, M., Linley,  
1218 E., Tonge, S., Hettiarachchi, N., *et al.* (2022). Determinants of SARS-CoV-2 anti-spike  
1219 antibody levels following BNT162b2 vaccination: cross-sectional analysis of 6,000 SIREN  
1220 study participants. medRxiv, 2022.2004.2021.22274025.
- 1221 Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B.,  
1222 Otter, A., Zuo, J., and Moss, P. (2022). Extended interval BNT162b2 vaccination enhances  
1223 peak antibody generation. *npj Vaccines* 7, 14.
- 1224 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,  
1225 Faustini, S., Al-Taei, S., Moore, S.C., *et al.* (2021a). Immunogenicity of standard and  
1226 extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699-5714.e5611.
- 1227 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,  
1228 Faustini, S., Al-Taei, S., Moore, S.C., *et al.* (2021b). Immunogenicity of standard and  
1229 extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699-5714.e5611.
- 1230 Reynolds, C.J., Pade, C., Gibbons, J.M., Otter, A.D., Lin, K.-M., Muñoz Sandoval, D.,  
1231 Pieper, F.P., Butler, D.K., Liu, S., Joy, G., *et al.* (2022). Immune boosting by B.1.1.529  
1232 (Omicron) depends on previous SARS-CoV-2 exposure. *Science*.

- 1233 Rosenberg, E.S., Dorabawila, V., Easton, D., Bauer, U.E., Kumar, J., Hoen, R., Hoefler, D.,  
1234 Wu, M., Lutterloh, E., Conroy, M.B., *et al.* (2021). Covid-19 Vaccine Effectiveness in New  
1235 York State. *New England Journal of Medicine* 386, 116-127.
- 1236 Rydzynski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D.,  
1237 Belanger, S., Abbott, R.K., Kim, C., Choi, J., *et al.* (2020). Antigen-Specific Adaptive  
1238 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease  
1239 Severity. *Cell* 183, 996-1012.e1019.
- 1240 Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z.,  
1241 Gaebler, C., Caskey, M., Nussenzweig, M.C., *et al.* (2021). Plasma Neutralization of the  
1242 SARS-CoV-2 Omicron Variant. *New England Journal of Medicine* 386, 599-601.
- 1243 Scurr, M.J., Lippiatt, G., Capitani, L., Bentley, K., Lauder, S.N., Smart, K., Somerville, M.S.,  
1244 Rees, T., Stanton, R.J., Gallimore, A., *et al.* (2022). Magnitude of venous or capillary blood-  
1245 derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. *Nature*  
1246 *Communications* 13.
- 1247 Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 184,  
1248 861-880.
- 1249 Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele,  
1250 S., Adland, E., Brown, H., Chinnakannan, S., *et al.* (2021). Two doses of SARS-CoV-2  
1251 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.  
1252 *Nature Communications* 12, 5061.
- 1253 Skowronski, D.M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot,  
1254 D., Prystajek, N., Tyson, J.R., Gilca, R., *et al.* (2022). Two-dose SARS-CoV-2 vaccine  
1255 effectiveness with mixed schedules and extended dosing intervals: test-negative design  
1256 studies from British Columbia and Quebec, Canada. *Clinical Infectious Diseases*, ciac290.
- 1257 Ssemaganda, A., Nguyen, H.M., Nuhu, F., Jahan, N., Card, C.M., Kiazzyk, S., Severini, G.,  
1258 Keynan, Y., Su, R.-C., Ji, H., *et al.* (2022). Expansion of cytotoxic tissue-resident CD8+ T  
1259 cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19  
1260 vaccination. *Nature Communications* 13.
- 1261 Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,  
1262 Gibbons, J.M., Le Bert, N., Tan, A.T., *et al.* (2022). Pre-existing polymerase-specific T cells  
1263 expand in abortive seronegative SARS-CoV-2. *Nature* 601, 110-117.
- 1264 Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin,  
1265 B., Phillips, E., Mallal, S., *et al.* (2022). SARS-CoV-2 vaccination induces immunological T  
1266 cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* 185, 847-  
1267 859.e811.
- 1268 Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N.,  
1269 Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., *et al.* (2021). Effectiveness of mRNA  
1270 BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the  
1271 USA: a retrospective cohort study. *The Lancet* 398, 1407-1416.
- 1272 Tartof, S.Y., Slezak, J.M., Puzniak, L., Hong, V., Xie, F., Ackerson, B.K., Valluri, S.R., Jodar,  
1273 L., and McLaughlin, J.M. (2022). Durability of BNT162b2 vaccine against hospital and  
1274 emergency department admissions due to the omicron and delta variants in a large health  
1275 system in the USA: a test-negative case&#x2013;control study. *The Lancet Respiratory*  
1276 *Medicine*.

- 1277 Tomic, A., Skelly, D.T., Ogbe, A., O'Connor, D., Pace, M., Adland, E., Alexander, F., Ali, M.,  
1278 Allott, K., Azim Ansari, M., *et al.* (2022). Divergent trajectories of antiviral memory after  
1279 SARS-CoV-2 infection. *Nature Communications* 13, 1251.
- 1280 UK Health Security Agency (2022). COVID-19 vaccine surveillance report: 12 May 2022  
1281 (week 19).
- 1282 Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Adams, L.,  
1283 Hobson, P., Hatipoglu, E., *et al.* (2021). AZD1222-induced neutralising antibody activity  
1284 against SARS-CoV-2 Delta VOC. *The Lancet* 398, 207-209.
- 1285 Ward, H., Whitaker, M., Flower, B., Tang, S.N., Atchison, C., Darzi, A., Donnelly, C.A., Cann,  
1286 A., Diggle, P.J., Ashby, D., *et al.* (2022). Population antibody responses following COVID-19  
1287 vaccination in 212,102 individuals. *Nature Communications* 13, 907.
- 1288 Wei, J., Matthews, P.C., Stoesser, N., Newton, J.N., Diamond, I., Studley, R., Taylor, N.,  
1289 Bell, J.I., Farrar, J., Kolenchery, J., *et al.* (2022a). Correlates of protection against SARS-  
1290 CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or  
1291 breakthrough infection in the UK general population. medRxiv, 2022.2011.2029.22282916.
- 1292 Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E.,  
1293 Cook, D., Bell, J.I., Newton, J.N., *et al.* (2022b). Antibody responses and correlates of  
1294 protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.  
1295 *Nature Medicine* 28, 1072-1082.
- 1296 Whitaker, H.J., Gower, C., Otter, A.D., Simmons, R., Kirsebom, F., Letley, L., Quinot, C.,  
1297 Ireland, G., Linley, E., Ribeiro, S., *et al.* (2021). Nucleocapsid antibody positivity as a marker  
1298 of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant,  
1299 vaccination, and choice of assay cut-off. medRxiv, 2021.2010.2025.21264964.
- 1300 Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Golemund, G.,  
1301 Hayes, A., Henry, L., Hester, J., *et al.* (2019). Welcome to the Tidyverse. *Journal of Open*  
1302 *Source Software* 4, 1686.
- 1303 Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Gálvez, R.I., Cortes,  
1304 F.H., Grifoni, A., Tarke, A., Chang, J., *et al.* (2022). Humoral and cellular immune memory to  
1305 four COVID-19 vaccines. *Cell* .  
1306  
1307



1308

	All	AZ	Pfizer Short	Pfizer Long	P <sup>e</sup> value
<b>Total N</b>	<b>684</b>	<b>92</b>	<b>84</b>	<b>508</b>	
<b>Dosing Intervals</b>					
Median Days	71	74	24	71	
Median Weeks	10	11	3	10	
Interquartile Range (Days)	63-77	64.75-78	21-27	66-78	
Maximum Days	158	158	38	120	
Minimum Days	14	53	0	0	
Range (Days)	14-158	53:158	0:38	0:120	
<b>Infection Status</b>					
Naïve, N (%)	342 (50.0%)	45 (51.1%)[0.01 ]	49 (41.7%)[1.3 ]	248 (52.4%)[0.18 ]	
Total Previous SARS-CoV-2, N (%)	342 (50.0%)	47 (48.9%)[0.01 ]	35 (58.3%)[1.28 ]	266 (48.8%)[0.18 ]	0.22
Previous infection at baseline , N <sup>a</sup>	269	39	30	200	
PCR+ Breakthrough Infections, N <sup>b</sup>	33	5	4	24	
Seroconverted During Study, N <sup>c</sup>	49	6	1	42	
<b>Age</b>					
Maximum Age	77	77	71	71	
Minimum Age	22	22	22	22	
Age Range	22-77	22-77	22-71	22-71	
Median Age In Years	43	43	45	43	
Interquartile Range Age	33-52.3	27-56	37-55	33-51.25	
<b>Sex</b>					
Female, N (%)	505 (73.8%)	68 (73.9%)[0.00 ]	50 (59.5%)[2.33 ]	387 (76.2%)[0.38 ]	
Male, N (%)	179 (26.2%)	24 (26.1%)[0.00 ]	34 (40.5%)[6.57 ]	121 (23.8%)[1.07 ]	0.006
<b>Ethnicity</b>					
White, N (%) <sup>d</sup>	464 (83.8%)	71 (79.8%)	56 (84.8%)	337 (84.5%)	
Asian, N (%) <sup>d</sup>	56 (10.1%)	12 (13.5%)	5 (7.6%)	39 (9.8%)	
Black, N (%) <sup>d</sup>	7 (1.3%)	0 (0.0%)	1 (1.5%)	6 (1.5%)	
Other, N (%) <sup>d</sup>	27 (4.9%)	6 (6.7%)	4 (6.1%)	17 (4.3%)	
Unreported, N	130	3	18	109	

1309

1310

1311

1312

<sup>a</sup>Previous infection at baseline (time of 1<sup>st</sup> vaccination) = previous PCR+ SARS-CoV-2 +/- anti-nucleocapsid IgG positive at baseline

<sup>b</sup>PCR+ Breakthrough infections include 9 re-infections who were in the “Previous infection at baseline” group

1313 <sup>c</sup>Seroconverted during study = No documented PCR+, lateral flow test or suspected SARS-CoV-2 infection,  
1314 but asymptomatic rise in anti-nucleocapsid IgG (MSD) above assay positivity threshold and > 2x baseline

1315 <sup>d</sup>Percentage of reported ethnicities

1316 <sup>e</sup>Differences between the groups were assessed using the Chi squared test.


1317

1318 **Table 1. Demographic characteristics of participants in the study**

1319

1320 **FIGURES AND FIGURE LEGENDS**

1321



1322


1323 **Figure 1. Study Design**

1324 Schematic representation of vaccination and phlebotomy time points.

1325 Figure created using Biorender.

1326

1327



1328


1329

**Figure 2. Comparison of T cell and IgG responses six months after the second dose of vaccine according to vaccine regimen and infection status.**

1330

1331 (A) Comparison of IFN $\gamma$  ELISpot responses to spike (S, ancestral strain) from  
 1332 cryopreserved peripheral blood mononuclear cells (PBMCs) in naïve (grey circles)  
 1333 participants 6 months after 2 doses of BNT162b2 (Pfizer-BioNTech) delivered with a  
 1334 short dosing interval (“Short”, 3-5 weeks, n=33), or a long dosing interval (“Long”, 6-  
 1335 17 weeks, n=116), or 6 months after 2 doses of AZD1222 (AstraZeneca) vaccine  
 1336 (“AZ”, n=29); or previously infected (closed red circles infected at baseline, open red  
 1337 circles infected during study) BNT162b2 short (n=13), previously infected BNT162b2  
 1338 long (n=94), and AZ (n=16) vaccinated individuals. (B) Effect of vaccine regimen and  
 1339 infection status on SARS-CoV-2 S-specific IgG responses in naïve short (n=38), long  
 1340 (n=170), and AZ (n=39); and previously infected short (n=18), long (n=99), and AZ

1341 (n=28) vaccinated individuals. (C) Effect of vaccine regime and infection status on  
1342 SARS-CoV-2 RBD-specific IgG responses in naïve short (n=38), long (n=169), and  
1343 AZ (n=37); and previously infected short (n=18), long (n=99), and AZ (n=28)  
1344 vaccinated individuals. (D) Association of membrane (M) and nucleocapsid (N)  
1345 protein specific T cell and SARS-CoV-2 N-specific IgG responses in participants 6  
1346 months after second dose, and 28 days after third dose (hence participants can have  
1347 >1 value), by infection status. ELISpot values are expressed as spot forming units  
1348 per million (SFU/10<sup>6</sup>) PBMCs. Data displayed are responses to peptide pools  
1349 representing the sum of S1 and S2 units of S (ancestral strain). IgG responses were  
1350 measured in serum 6 months after the second dose using multiplexed MSD  
1351 immunoassays and are shown in arbitrary units (AU)/mL. Bars represent the median.  
1352 Vaccine regimes and infection status were compared with Kruskal-Wallis and Dunn's  
1353 multiple comparisons test (A-C) and Spearman's tests (D), with 2-tailed p-values  
1354 shown above linking lines. Where p-values are absent, comparison was not  
1355 statistically significant (p>0.05). Dashed lines in (D) represent thresholds for a  
1356 positive response: SARS-CoV-2 N IgG - based on the mean concentrations  
1357 measured in 103 pre-pandemic sera + 3 Standard Deviations (3874 AU/ml); SARS-  
1358 CoV-2 M & N IFN $\gamma$  ELISpot assay – mean + 2 Standard Deviations of the DMSO  
1359 wells across all experiments in the study (33 SFU/10<sup>6</sup>).  
1360



1361

1362

1363 **Figure 3. Time course of T cell, binding IgG and B cell responses for all**  
1364 **participants, and cross section of responses one month post dose 3 after 2**  
1365 **doses of BNT162b2 (short or long interval) or AZD1222 vaccine.**

1366 (A) Time course comparison of T cell responses to SARS-CoV-2 spike by IFN $\gamma$   
1367 ELISpot assay for all vaccine regimens up to 6 months post third dose (n=613). (B)

1367 Time course comparison of IgG antibody response to SARS-CoV-2 spike by  
1368 MesoScale Discovery assay for all vaccine regimens up to 6 months post third dose  
1369 (n=680). (C) Time course comparison of B cell responses to SARS-CoV-2 spike by B  
1370 cell ELISpot assay for all vaccine regimens up to one month post third dose. (D)  
1371 Comparison of T cell responses one month after the third booster dose by primary  
1372 vaccine regimen (BNT162b2 Short, Long or AZD1222). (E) Comparison of IgG  
1373 antibody responses one month after the third booster dose by primary vaccine  
1374 regimen. (F) Comparison of B cell responses one month after the third booster dose  
1375 by primary vaccine regimen. Grey circles = naïve individuals, red circles = hybrid  
1376 immunity. Bars represent the median. Comparisons within groups were tested with  
1377 the Kruskal-Wallis nonparametric test and Dunn's multiple comparisons correction,  
1378 with 2-tailed p values shown above linking lines for significant differences with  
1379  $p \leq 0.05$ . Unpaired comparisons between naïve and hybrid immune time points were  
1380 tested with the Mann Whitney test.

1381

1382


1383

1384

1385

1386

1387



1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399


1400

### Figure 4. Analysis of spike-specific T cell responses by flow cytometry

Cryopreserved PBMCs from a subset of 95 participants who received BNT162b2 (Pfizer/BioNTech) with a short or long dosing interval, or AZD1222 (AstraZeneca), one month after the second dose, were analysed by intracellular cytokine staining and flow cytometry. The individual cytokine expression levels of total IFN $\gamma$ , IL2 or TNF are shown as a percentage of (A) the CD4 $^+$  T cell population (top panels), or (B) the CD8 $^+$  T cell population (bottom panels). Populations were analysed by gating on single, live, CD3 $^+$  cells (Supplementary figure 1). Short = BNT162b2 short interval; Long = BNT162b2 long interval; AZ = AZD1222. Naïve participants are shown as grey circles and hybrid immunity group are red circles. Box plots represent the median, IQR and whiskers 1.5 x the IQR. (C) The T cell populations responsible for IFN $\gamma$  or IL2 expression were assessed as the proportion of IFN $\gamma$  or IL2 expressed

1401 by CD4<sup>+</sup> T cells, calculated by dividing the cytokine production in CD4<sup>+</sup> T cells by the  
1402 total cytokine production in response to spike in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. (D)  
1403 Polyfunctionality was evaluated by combined expression of IFN $\gamma$ , IL2 and TNF in  
1404 CD4<sup>+</sup> and CD8<sup>+</sup> T cells, showing the percentage of cells making all three cytokines.  
1405 Naïve short: n=20, Naïve long: n=15, Naïve AZ n=14, Hybrid immunity short: n=13,  
1406 Hybrid immunity long: n=17, Hybrid immunity AZ: n= 16. Unpaired comparisons  
1407 across two groups were performed using the Mann Whitney test with 2-tailed p  
1408 values shown above linking lines when 2-tailed p $\leq$ 0.05.  
1409





1410

1411

**Figure 5. T cell proliferation to SARS-CoV2 at 6 months after the primary vaccine course of 2 doses of BNT162b2 or AZD1222**


1412

1413 T cell proliferation to SARS-CoV2 peptide pools was assessed by flow cytometry in  
 1414 PBMC from 73 participants who had received either BNT162b2 with a short or long  
 1415 vaccine dosing interval or AZD1222 vaccine and were either naïve or were  
 1416 previously infected (either at baseline or during the course of the study). (A) Relative  
 1417 frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T cells proliferating to individual peptide pools spike  
 1418 S1, spike S2, membrane (M) and nucleocapsid (N) protein in naïve (n=39) and  
 1419 hybrid immunity (n=34) individuals. Grey colour=missing value. (B, D) Proliferation to  
 1420 S1 and S2 and (C, E) M and N protein in CD4<sup>+</sup> (B, C) and CD8<sup>+</sup> (D, E) T cells are  
 1421 shown across the 3 vaccine regimens separated by exposure status (naïve versus  
 1422 hybrid immunity). Individual data points and median with IQR are displayed for naïve  
 1423 short: n=16, naïve long: n=15, naïve AZ: n=8, hybrid immunity short: n=11, hybrid  
 1424 immunity long: n=12, hybrid immunity AZ: n=11. Comparisons between naïve and

1425 hybrid immunity within each vaccine regimen were performed using the Mann  
1426 Whitney test, and comparisons between the three vaccine regimens within the naïve  
1427 and previously infected groups was performed using the Kruskal Wallis test and  
1428 Dunn's multiple comparisons correction. 2-tailed P values are shown only for  
1429 statistically significant comparisons ( $p \leq 0.05$ ). Fold change between medians of two  
1430 groups are shown in brackets next to or under p value. (Fold change is not shown for  
1431 those comparisons where there was no proliferation detected in one of the groups.)  
1432 Grey circles = naïve individuals, red circles = participants with hybrid immunity.  
1433

1434

1435



1436

1437

**Figure 6. Neutralizing antibody and ACE2 inhibition titre profiles against SARS-CoV-2 variants of concern 6 months after 2 doses of BNT162b2 or AZD1222 and one month after a third vaccine with BNT162b2.**

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450


1451

1452

Focus Reduction Neutralization Assay 50% (FRNT<sub>50</sub>) antibody titres against the Victoria isolate (orange), delta (B.1.617.2, purple) and omicron BA.1 (B.1.1.529 BA.1, blue) taken from infection-naïve participants. FRNT<sub>50</sub> is the reciprocal dilution of the concentration of serum required to produce a 50% reduction in infectious focus forming units of virus in Vero cells (ATCC CCL-81). Participants either received 2 doses of BNT162b2 (Pfizer-BioNTech) vaccine delivered in a short (“Short”, 3-5 weeks, n=20) or long (“Long”, 6-17 weeks, n=20) dosing interval, or 2 doses of AZD1222 (AstraZeneca) vaccine (“AZ”, n=16). Neutralizing antibody titres are shown in (A) 6 months after the second dose, and (C) for the same individuals, one month after a third “booster” dose of mRNA vaccine for all participants. Geometric mean neutralizing titres with 95% confidence intervals are shown. (E) Comparison of the data from (A) and (C), plotted as means with error bars by vaccine regimen 6 months after the second vaccine (V2+ 6 months), one month after

1453 the third “booster” mRNA vaccine (V3+1 month). The range of fold change (median)  
1454 between V2+6 months and V3+1 month for the three vaccine regimens (Short –  
1455 dashed line, Long – solid line, and AZ – dotted line) is shown in brackets for each  
1456 variant. Data in panels (A), (C) and (E) from the Short group (n=20) has been  
1457 previously published (Dejnirattisai, Huo et al. 2022). (B) Impact of Short or Long  
1458 BNT162b2 vaccine dosing interval and AZ on the ability of sera to inhibit ACE2  
1459 binding to SARS-CoV-2 spike (Victoria isolate, delta (B.1.617.2), Omicron BA.1  
1460 (B.1.1.529 BA.1), alpha (B.1.1.7), beta (B.1.351) and gamma (P.1) 6 months after  
1461 the second dose and (D) one month after a third “booster” dose with mRNA vaccine.  
1462 ACE2 inhibition was analysed using a multiplexed MSD® assay and performed at a  
1463 serum dilution of 1:10 at V2 + 6 months and 1:100 at V3+1 months. Data are shown  
1464 as percentage of inhibition. Bars represent the median with 95% confidence  
1465 intervals. Naïve, Short: n=20; Naïve, Long: n=20; Naïve, AZ: n=16 for V2+6 months;  
1466 Naïve, Short: n=19; Naïve, Long: n=20; Naïve, AZ: n=10 for V3+1 month. Vaccine  
1467 regimens were compared with the Kruskal-Wallis nonparametric test and Dunn’s  
1468 multiple comparisons correction, with 2-tailed p values shown above linking lines  
1469 when 2-tailed  $p \leq 0.05$ , and fold changes are shown between the columns.  
1470  
1471  
1472  
1473

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1474

1475

1476 **Figure 7. Antibody responses to omicron subvariants up to 6 months post**

1477 **dose 3.** IgG binding measured on the MSD platform to spike from ancestral SARS-

1478 CoV-2 (orange) and the BA.1 (blue), BA.2 (grey), BA.3 (brown), BA.3 (maroon), BA.5

1479 (green) omicron variants at 6 months after two doses of BNT162b2 (A) and one

1480 month post dose 3 of BNT162b2 vaccine in infection naïve participants (n = 21) (B)

1481 and 6 months post dose 3 of BNT162b2 vaccine (C) in both infection naïve

1482 participants (n=60) and in participants who became infected with an Omicron variant




between 1 and 6 months post dose 3 (n=55). ACE2 inhibition by plasma from the

1483 same donors in A-C at 6 months post dose 2 (D), one month post dose 3 (E) and 6  
1484 months post dose 3 (F) ACE2 inhibition was performed at a serum dilution of 1 in  
1485 100 to account for saturation of the assay, as seen in figure 6. Comparisons between  
1486 responses to ancestral and Omicron variants were made using Friedman's test, with  
1487 2-tailed p-values of significant differences ( $p \leq 0.05$ ) shown above linking line. (G)  
1488 Neutralising antibody was measured at one month post dose 3 and 6 months post  
1489 dose 3 by focus reduction neutralisation titre 50% (FRNT<sub>50</sub>) for Victoria strain  
1490 (orange), BA.1 (blue), BA.2 (grey) and BA.5 (green) omicron variants in participants  
1491 who remained infection naïve (n=33) and those who became infected in between  
1492 one and 6 months post dose 3 (n=11). Filled circles indicate participants who remain  
1493 infection naïve, participants who became infected with an omicron variant between  
1494 one month and 6 months after the third vaccine dose are indicated in unfilled circles.  
1495 Paired comparisons between one and 6 months post vaccine were tested using the  
1496 Wilcoxon signed rank test, and comparis'n's between groups were tested using the  
1497 Mann Whitney test.


1498

1499

## T cell responses to Omicron



## B cell responses to Omicron BA.1



1501 **Figure 8. Comparison of cytokine response at 6 months post dose 2 against**  
1502 **ancestral strain and omicron BA.1 variant according to infection status.**  
1503 **Longitudinal comparison of T cell and B cell responses against ancestral**  
1504 **strain and omicron BA.1 variant according to vaccine regimen and infection**  
1505 **status.**


1506 (A) Comparison of percentage IFN $\gamma$ , TNF and IL2 positive CD4 T cells against  
1507 ancestral strain and omicron BA.1 variant by intracellular cytokine staining of  
1508 cryopreserved peripheral mononuclear cells (PBMCs) in either infection naïve  
1509 participants or participants with hybrid immunity. (B) Comparison of percentage  
1510 IFN $\gamma$ , TNF and IL2 positive CD8 T cells against ancestral strain and omicron BA.1  
1511 variant by intracellular cytokine staining of PBMCs in either infection naïve  
1512 participants or participants with hybrid immunity. Pairwise comparison of T cell  
1513 responses to spike from ancestral strain and omicron BA.1 variant from PBMCs by  
1514 IFN $\gamma$  ELISpot assay (C) in participants 6 months post primary vaccine course (2  
1515 doses of BNT162b2 or AstraZeneca), n=215, and (D) one month post third  
1516 BNT162b2 vaccine dose, n=175. Displayed are responses to peptide pools  
1517 representing the sum of S1 and S2 units of S from ancestral strain and omicron  
1518 variant. (E) Pairwise comparison of IFN $\gamma$  ELISpot responses in a subset of  
1519 participants (n=36) to only the 51 out of 178 peptides spanning spike that have  
1520 mutations in omicron BA.1 compared to the ancestral strain. (F) T cell responses to  
1521 spike from ancestral strain and omicron BA.1, BA.2 and BA.4/5 variants in PBMCs  
1522 from naïve (n=28) and hybrid immune (n=46) donors by IFN $\gamma$  ELISpot assay. (G)  
1523 Pairwise comparison of B cell responses to S in ancestral strain and omicron BA.1  
1524 variant from PBMCs in participants one month post vaccine dose 2 (n=12); (H) 6  
1525 months post second vaccine dose (n=43); (I) one month post third vaccine dose  
1526 (n=80). Orange circles = responses against Victoria variant; blue circles = responses  
1527 against omicron BA.1 variant. Displayed are responses to peptide pools representing  
1528 S1 and S2 units of S from ancestral and omicron variants. ELISpot values are  
1529 expressed as antibody SFU/10<sup>6</sup> PBMCs. Horizontal lines represent median values.  
1530 Comparisons between responses to ancestral and Omicron variants were made  
1531 using Wilcoxon matched-pairs signed rank test, with 2-tailed p-values of significant  
1532 differences (p $\leq$ 0.05) shown above linking line.



## SUPPLEMENTARY INFORMATION

Supplementary Table 2. Antibodies used for intracellular cytokine staining and proliferation


Marker name	Fluorochrome	Clone	Species reactivity	Host species	Isotype	Manufacturer	Catalogue number	Dilution used
CD3	PerCP	UCHL1	human	mouse	IgG1, $\kappa$	Biolegend	300428	100
CD3	FITC	UCHL1	human	mouse	IgG1, $\kappa$	Biolegend	300440	50
CD4	APC	RPA-T4	human	mouse	IgG1, $\kappa$	Biolegend	300514	200
CD8	PE-Cy7	RPA-T8	human	mouse	IgG1, $\kappa$	Biolegend	301012	200
CD8	BV510	RPA-T8	human	mouse	IgG1, $\kappa$	Biolegend	301048	600
CD14	APC-Fire750	M5E2	human	mouse	IgG2a, $\kappa$	Biolegend	301854	200
IFN- $\gamma$	PE	4S.B3	human	mouse	IgG1, $\kappa$	Biolegend	502508	50
TNF	FITC	MAb11	human	mouse	IgG1, $\kappa$	Biolegend	502908	40
IL-2	PE-Cy7	MQ1-17H12	human	rat	IgG2a, $\kappa$	eBioscience	25-7029-41	100



**Figure S1. Gating strategy for T cell cytokine secretion (ICS) and proliferation**  
 (A) For ICS assays single cells were gated using forward scatter (FSC)- area (A) and FSC- height (H) followed by a lymphocyte gate using FSC-A and side scatter (SSC)- A. Live CD3<sup>+</sup> T cells were gated based on exclusion of dead cells (LD-NiR) and monocytes (CD14 APC Fire-750) as well as positivity for CD3 PerCP. T cell subsets were identified based on staining for CD4 APC and CD8 BV510 respectively and

expression of cytokines (IFN $\gamma$ , TNF, IL-2) was then identified in the CD4<sup>+</sup>CD8<sup>-</sup> gate as well as the CD8<sup>+</sup>CD4<sup>-</sup> gate. Representative gating is shown for the DMSO negative control and the PMA/Ionomycin positive control. In the case of PMA/Ionomycin the CD4<sup>+</sup> gate was extended all the way to the CD4<sup>-</sup> population due to downregulation of expression upon treatment (not shown in the figure).


(B) For proliferation assays, lymphocytes were gated FSC-A and SSC-A parameters, followed by two subsequent single cell gates on FSC-H and width (W) as well as SSC-H and W to exclude doublets. From there live T cells were gated (LD-NiR low CD3<sup>+</sup>) and T cell subsets were identified (CD4<sup>+</sup>CD8<sup>-</sup> and CD8<sup>+</sup>CD4<sup>-</sup>) using CD4<sup>+</sup> APC and CD8<sup>+</sup> PE-Cy7. Within the CD4<sup>+</sup> and the CD8<sup>+</sup> T cell gate proliferating cells were identified by gating on cells with reduced CTV (CellTrace™ Violet) fluorescence intensity.



**Figure S2. Comparison of T cell and IgG responses in those previously infected at baseline, infected during study, or infected at any time, at six months post second vaccine.**

(A) Comparison of IFN $\gamma$  ELISpot responses to S (ancestral strain) from cryopreserved PBMCs in short naïve (n=33), infected during study (n=2), previously infected at baseline (n=11) individuals; long naïve (n=116), infected during study (n=32), previously infected at baseline (n=62) individuals; AZ naïve (n=29), infected during study (n=6), previously infected at baseline (n=10) individuals. (B) Effect of vaccine regime and infection status on SARS-CoV-2 S-specific IgG responses in short naïve (n=38), infected during study (n=2), previously infected at baseline (n=21); long naïve (n=132), infected during study (n=36), previously infected at baseline (n=96); AZ naïve (n=27), infected during study (n=7), previously infected at baseline (n=23). Grey circles = naïve; solid red circles = previous infection at baseline; open red circles = infected during study. ELISpot values are expressed as SFU/10<sup>6</sup> PBMCs, with values displayed responses to peptide pools representing S1 and S2 units of S (ancestral strain). IgG responses were measured in serum 6 months after the second dose using multiplexed MSD immunoassays and are shown in arbitrary units (AU)/mL. Horizontal bars represent the median. Vaccine regimens and vaccine status was compared using the Kruskal-Wallis test and Dunn's multiple

comparisons correction, with 2-tailed p-values shown above linking lines where significant ( $p \leq 0.05$ ). ns = not significant.



**Figure S3. Time course of T cell, binding IgG and B cell responses 1 and 6 months after 2 doses of BNT162b2 (short or long interval) or AZD1222 vaccine:** Responses are shown one and 6 months after 2 doses and following a third dose of BNT162b2 for (A) T cell responses to SARS-CoV-2 spike by IFN $\gamma$  ELISpot assay after BNT162b2 (Pfizer-BioNTech) delivered with a short dosing interval (“Short”, 3-5 weeks, n=11-44 naïve, n=10-24 hybrid immunity), (B) IgG responses to SARS-CoV-2 spike by MesoScale Discovery (MSD) assay after BNT162b2 Short (n=24-59 naïve, n=8-24 hybrid immunity) and (C) B cell responses to SARS-CoV-2 spike by B cell Elispot assay after BNT162b2 Short (n=6-13 naïve, n=1-4 hybrid immunity). Responses are shown 1 and 6 months after 2 doses and following a third dose of BNT162b2 for (D) T cell responses to spike after a long interval (“Long”, 6-17 weeks, n=49-189 naïve, n=31-156 hybrid immunity), (E) IgG responses to spike by MSD assay after BNT162b2 Long (n=123-178 naïve, 78-203 hybrid immunity) and (F) B cell responses to spike after BNT162b2 Long (n=12-47 naïve, n=22-39 hybrid immunity). Responses are shown 1 and 6 months after 2 doses and following a third dose of BNT162b2 for (G) T cell responses to spike after AZD1222 (AstraZeneca) vaccine (“AZ”, n=18-26 naïve, 6-26 hybrid immunity), (H) IgG responses to spike by

MSD assay after AZD1222 (n=28-54 naïve, n=16-44 hybrid immunity) and (I) B cell responses to spike after AZD1222 (n=5-8 naïve, n=7-10 hybrid immunity).





Figure S4. T cell and IgG Antibody responses to membrane protein, nucleocapsid protein and receptor binding domain.


T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of BNT162b2 short dosing interval. (A) IFN $\gamma$  ELISpot responses in PBMCs, (B) IgG against receptor binding domain (RBD) and (C) IgG against nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of BNT162b2 long dosing interval. (D) IFN $\gamma$  ELISpot responses in PBMCs, (E) IgG against receptor binding domain (RBD) and (F) IgG against nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of AstraZeneca. (G) IFN $\gamma$  ELISpot responses in PBMCs, (H) IgG against receptor binding domain (RBD) and (I) IgG against nucleocapsid (N). Grey circles = naïve individuals, red circles = hybrid immunity. Bars represent the median. Comparisons are with the Kruskal-Wallis nonparametric test and Dunn's multiple comparisons correction, with 2-tailed p values shown above linking lines for significant differences with  $p \leq 0.05$ .





**Figure S5. Correlation between ACE2 inhibition and neutralising antibodies.**

Correlation between the percentage of ACE2 inhibition and neutralisation titres against (A) Victoria, (B) Delta (B.1.617.2) and (C) Omicron BA.1 (B.1.1.529 BA.1), expressed as Focus Reduction Neutralization Assay 50% (FRNT<sub>50</sub>), determined in infection-naïve participants after receiving two doses of BNT162b2 (Pfizer-BioNTech) vaccine delivered in a short (“Short”, 3-5 weeks, n=20) or long (“Long”, 6-14 weeks, n=20) dosing interval, or two doses of AZD1222 (AstraZeneca) vaccine (“AZ”, n=15) 6 months after the second dose. Correlation between the percentage of ACE2 inhibition and neutralisation titres against (D) Ancestral, (E) Omicron BA.1 and (F) Omicron BA.2 expressed as half maximal inhibitory concentration (IC<sub>50</sub>), determined in infection-naïve participants one month after third vaccine dose. Correlation between the percentage of ACE2 inhibition and neutralisation titres against (G) Ancestral, (H) Omicron BA.1 and (I) Omicron BA.2 expressed as IC<sub>50</sub>, determined in infection-naïve participants 6 months after third vaccine dose. Pairwise correlations were assessed using Spearman’s rank-order correlation. Rhombus = Pfizer short, triangle= Pfizer Long, circle=AZ.



**Figure S6. T cell cytokine responses and proliferation to the omicron (BA.1) variant 6 months after the primary vaccine course with BNT162b2 or AZD1222.** (A) Combined data from naïve (grey) and hybrid immunity (red) participants shows cytokine responses (IFN- $\gamma$  and IL-2) in CD4 $^+$  T cells at 6 months post second dose of either BNT162b2 (short and long dosing interval) or AZD1222. Proliferative responses of CD4 $^+$  and CD8 $^+$  T cells to SARS-CoV2 spike (S1+S2) from the ancestral strain were compared to the omicron BA.1 variant in a subset of (B, D) naïve (n=9) and (C, E) hybrid immunity (hybrid immunity, n=27) participants from all three vaccine regimens 6 months after the second dose. Individual data points are presented, and paired values are connected with a line. Paired testing was performed using Wilcoxon signed rank test and 2-tailed p values for significant differences (p $\leq$ 0.05) are displayed. Closed circles = ancestral spike, open circles = omicron BA.1 spike, Grey = naïve individuals, red= individuals with hybrid immunity.